Pendahuluan
Halaman ini memberikan analisis komprehensif tentang sejarah perdagangan orang dalam yang diketahui dari Mark N Lampert. Orang dalam adalah pejabat, direktur, atau investor signifikan dalam suatu perusahaan. Adalah ilegal bagi orang dalam untuk melakukan perdagangan di perusahaan mereka berdasarkan informasi spesifik yang tidak dipublikasikan. Ini tidak berarti bahwa mereka dilarang melakukan perdagangan apa pun di perusahaan mereka sendiri. Namun, mereka harus melaporkan semua perdagangan kepada SEC melalui Formulir 4. Terlepas dari pembatasan ini, penelitian akademis menunjukkan bahwa orang dalam - secara umum - cenderung mengungguli pasar di perusahaan mereka sendiri.
Rata-rata Profitabilitas Perdagangan
Profitabilitas perdagangan rata-rata adalah pengembalian rata-rata dari semua pembelian pasar terbuka yang dilakukan oleh orang dalam dalam tiga tahun terakhir. Untuk menghitung ini, kami memeriksa setiap pembelian pasar terbuka yang tidak direncanakan yang dilakukan oleh orang dalam, tidak termasuk semua perdagangan yang ditandai sebagai bagian dari rencana perdagangan 10b5-1. Kami kemudian menghitung kinerja rata-rata dari perdagangan tersebut selama 3, 6, dan 12 bulan, dengan merata-ratakan setiap durasi tersebut untuk menghasilkan metrik kinerja akhir untuk setiap perdagangan. Terakhir, kami merata-ratakan semua metrik kinerja untuk menghitung metrik kinerja untuk orang dalam. Daftar ini hanya mencakup orang dalam yang telah melakukan setidaknya tiga perdagangan dalam dua tahun terakhir.
Jika profitabilitas perdagangan orang dalam ini adalah "N/A", maka orang dalam tersebut belum melakukan pembelian di pasar terbuka dalam tiga tahun terakhir, atau perdagangan yang mereka lakukan terlalu baru untuk menghitung metrik kinerja yang andal.
Frekuensi Pembaruan: Setiap Hari
Lihat daftar pedagang dalam perusahaan yang paling menguntungkan.
Perusahaan dengan Posisi Orang Dalam yang Dilaporkan
Pengajuan SEC menunjukkan bahwa Mark N Lampert telah melaporkan kepemilikan atau perdagangan di perusahaan-perusahaan berikut:
Cara Membaca Grafik
Grafik berikut menunjukkan kinerja saham sekuritas setelah setiap perdagangan pasar terbuka yang tidak direncanakan yang dilakukan oleh Mark N Lampert. Perdagangan yang tidak direncanakan adalah perdagangan yang tidak dilakukan sebagai bagian dari rencana perdagangan 10b5-1. Kinerja saham digambarkan sebagai perubahan persentase kumulatif dalam harga saham. Misalnya, jika perdagangan orang dalam dilakukan pada 1 Januari 2019, grafik akan menunjukkan perubahan persentase harian sekuritas hingga saat ini. Jika harga saham naik dari $10 menjadi $15 selama periode ini, perubahan persentase kumulatif dalam harga saham akan menjadi 50%. Perubahan harga dari $10 menjadi $20 akan menjadi 100%, dan perubahan harga dari $10 menjadi $5 akan menjadi -50%.
Pada akhirnya, kita mencoba menentukan seberapa erat korelasi perdagangan orang dalam dengan pengembalian berlebih (positif atau negatif) pada harga saham untuk melihat apakah orang dalam tersebut mengatur waktu perdagangannya untuk mendapatkan keuntungan dari informasi orang dalam. Pertimbangkan situasi di mana orang dalam melakukan hal ini. Dalam situasi ini, kita akan mengharapkan (a) pengembalian positif setelah pembelian, atau (b) pengembalian negatif setelah penjualan. Dalam kasus (a), grafik PEMBELIAN akan menunjukkan serangkaian kurva yang miring ke atas, menunjukkan pengembalian positif setelah setiap transaksi pembelian. Dalam kasus (b), grafik PENJUALAN akan menunjukkan serangkaian kurva yang miring ke bawah, menunjukkan pengembalian negatif setelah setiap transaksi penjualan.
Namun, ini saja tidak cukup untuk menarik kesimpulan. Jika, misalnya, harga saham perusahaan berada dalam tren kenaikan non-siklikal selama bertahun-tahun, maka kita akan mengharapkan semua plot pasca-pembelian memiliki kemiringan ke atas. Demikian pula, penurunan non-siklikal selama bertahun-tahun akan menghasilkan plot pasca-perdagangan dengan kemiringan ke bawah. Tak satu pun dari grafik ini akan menunjukkan aktivitas perdagangan orang dalam.
Indikator terkuat adalah situasi di mana harga saham sangat siklikal, dan terdapat sinyal positif pada grafik PEMBELIAN dan plot negatif pada grafik PENJUALAN. Situasi ini akan sangat menunjukkan adanya orang dalam yang mengatur waktu perdagangan untuk keuntungan finansial mereka.
Pembelian Orang Dalam CALA / Calithera Biosciences, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam CALA / Calithera Biosciences, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam CAPS / Capstone Holding Corp. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam CAPS / Capstone Holding Corp. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam CGEM / Cullinan Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam CGEM / Cullinan Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam CTMX / CytomX Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam CTMX / CytomX Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam CYTK / Cytokinetics, Incorporated - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam CYTK / Cytokinetics, Incorporated - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam ELDN / Eledon Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam ELDN / Eledon Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam EPIX / ESSA Pharma Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam EPIX / ESSA Pharma Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam FDMT / 4D Molecular Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam FDMT / 4D Molecular Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam IDYA / IDEAYA Biosciences, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam IDYA / IDEAYA Biosciences, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam INFIQ / Infinity Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam INFIQ / Infinity Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam KYMR / Kymera Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam KYMR / Kymera Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam MLTX / MoonLake Immunotherapeutics - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam MLTX / MoonLake Immunotherapeutics - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam MRUS / Merus N.V. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam MRUS / Merus N.V. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam OLMA / Olema Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam OLMA / Olema Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam RIGL / Rigel Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam RIGL / Rigel Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam RPTX / Repare Therapeutics Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam RPTX / Repare Therapeutics Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam SNDX / Syndax Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam SNDX / Syndax Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam VSTM / Verastem, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam VSTM / Verastem, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam XENE / Xenon Pharmaceuticals Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam XENE / Xenon Pharmaceuticals Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam XOMAO / XOMA Royalty Corporation - Preferred Stock - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam XOMAO / XOMA Royalty Corporation - Preferred Stock - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di CALA / Calithera Biosciences, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Sejarah Perdagangan Orang Dalam
Tabel ini menunjukkan daftar lengkap transaksi orang dalam yang dilakukan oleh Mark N Lampert sebagaimana diungkapkan kepada Komisi Bursa Efek (Securities Exchange Commission/SEC).
Tanggal File | Tanggal Transaksi | Formulir | Ticker | Keamanan | Kode | Saham | Sisa Saham | Persen Ubah |
Bagikan Harga |
Tran Nilai |
Sisa Nilai |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
S - Sale | -11 | 560,797 | 0.00 | 1.88 | -21 | 1,053,121 | |
2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
S - Sale | -66 | 4,726,743 | 0.00 | 1.88 | -124 | 8,876,351 | |
2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
S - Sale | -79 | 6,194,145 | 0.00 | 1.88 | -148 | 11,631,985 | |
2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
X - Other | 203,336 | 560,808 | 56.88 | 0.00 | 20 | 56 | |
2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
X - Other | 1,235,030 | 4,726,809 | 35.37 | 0.00 | 124 | 473 | |
2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
X - Other | 1,481,634 | 6,194,224 | 31.44 | 0.00 | 148 | 619 | |
2025-07-01 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 58,780 | 353,412 | 19.95 | 44.00 | 2,586,320 | 15,550,128 | |
2025-07-01 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 115,783 | 2,219,858 | 5.50 | 44.00 | 5,094,452 | 97,673,752 | |
2025-07-01 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 142,604 | 2,798,795 | 5.37 | 44.00 | 6,274,576 | 123,146,980 | |
2025-06-17 |
|
4 | CBIO |
GLYCOMIMETICS INC
Common Stock |
J - Other | 56,079 | 62,383 | 889.58 | ||||
2025-06-17 |
|
4 | CBIO |
GLYCOMIMETICS INC
Common Stock |
J - Other | 556,617 | 593,740 | 1,499.39 | ||||
2025-06-17 |
|
4 | CBIO |
GLYCOMIMETICS INC
Common Stock |
J - Other | 657,308 | 707,116 | 1,319.68 | ||||
2025-05-20 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -265,316 | 1,267,545 | -17.31 | 27.10 | -7,190,064 | 34,350,470 | |
2025-05-20 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -127,407 | 1,322,758 | -8.79 | 27.10 | -3,452,730 | 35,846,742 | |
2025-05-19 |
|
4 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
D - Sale to Issuer | -855,211 | 0 | -100.00 | ||||
2025-05-19 |
|
4 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
D - Sale to Issuer | -6,777,935 | 0 | -100.00 | ||||
2025-05-19 |
|
4 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
D - Sale to Issuer | -8,679,726 | 0 | -100.00 | ||||
2025-01-28 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -149,975 | 0 | -100.00 | 26.10 | -3,914,348 | ||
2025-01-28 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -75,287 | 0 | -100.00 | 26.10 | -1,964,991 | ||
2025-01-28 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -85,776 | 1,532,861 | -5.30 | 26.10 | -2,238,754 | 40,007,672 | |
2025-01-28 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -339,679 | 1,450,165 | -18.98 | 26.10 | -8,865,622 | 37,849,306 | |
2025-01-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -22,740 | 347,970 | -6.13 | ||||
2025-01-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -161,810 | 2,003,966 | -7.47 | ||||
2025-01-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -235,450 | 2,655,977 | -8.14 | ||||
2024-12-17 |
|
4 | PVLA |
PALVELLA THERAPEUTICS, INC.
Common Stock, $0.001 par value |
J - Other | 29,648 | 38,961 | 318.35 | ||||
2024-12-17 |
|
4 | PVLA |
PALVELLA THERAPEUTICS, INC.
Common Stock, $0.001 par value |
J - Other | 174,958 | 282,223 | 163.11 | ||||
2024-12-17 |
|
4 | PVLA |
PALVELLA THERAPEUTICS, INC.
Common Stock, $0.001 par value |
J - Other | 234,323 | 371,916 | 170.30 | ||||
2024-12-04 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -153,441 | 370,710 | -29.27 | ||||
2024-12-04 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -1,418,736 | 2,165,776 | -39.58 | ||||
2024-12-04 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -1,797,527 | 2,891,427 | -38.34 | ||||
2024-11-13 |
|
4 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | -240,000 | 87,911 | -73.19 | ||||
2024-11-13 |
|
4 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | -2,378,000 | 662,970 | -78.20 | ||||
2024-11-13 |
|
4 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | -3,062,000 | 830,237 | -78.67 | ||||
2024-10-31 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
S - Sale | -64,617 | 176,692 | -26.78 | 14.30 | -924,023 | 2,526,696 | |
2024-10-31 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
S - Sale | -396,963 | 1,367,257 | -22.50 | 14.30 | -5,676,571 | 19,551,775 | |
2024-10-31 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
S - Sale | -538,420 | 1,794,218 | -23.08 | 14.30 | -7,699,406 | 25,657,317 | |
2024-10-08 |
|
4 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
S - Sale | -132,549 | 1,287,768 | -9.33 | 50.00 | -6,627,662 | 64,390,460 | |
2024-10-08 |
|
4 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
S - Sale | -836,862 | 8,168,838 | -9.29 | 50.00 | -41,844,439 | 408,454,970 | |
2024-10-08 |
|
4 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
S - Sale | -1,030,589 | 10,235,089 | -9.15 | 50.00 | -51,531,099 | 511,770,826 | |
2024-08-01 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
3,892,237 | ||||||||
2024-08-01 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
3,040,970 | ||||||||
2024-08-01 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
327,911 | ||||||||
2024-05-13 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 75,431 | 220,460 | 52.01 | ||||
2024-05-13 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 821,121 | 2,633,679 | 45.30 | ||||
2024-05-13 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1,031,385 | 3,361,803 | 44.26 | ||||
2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Non-Voting Common Stock, $0.001 par value |
U - Other | -341,547 | 0 | -100.00 | ||||
2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Common Stock, $0.001 par value |
U - Other | -185,388 | 0 | -100.00 | ||||
2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Non-Voting Common Stock, $0.001 par value |
U - Other | -2,076,085 | 0 | -100.00 | ||||
2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Common Stock, $0.001 par value |
U - Other | -1,367,838 | 0 | -100.00 | ||||
2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Non-Voting Common Stock, $0.001 par value |
U - Other | -2,870,985 | 0 | -100.00 | ||||
2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Common Stock, $0.001 par value |
U - Other | -1,734,960 | 0 | -100.00 | ||||
2024-01-26 | 3 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
8,679,726 | ||||||||
2024-01-26 | 3 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
6,777,935 | ||||||||
2024-01-26 | 3 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
855,211 | ||||||||
2023-12-20 |
|
4 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
S - Sale | -896,366 | 0 | -100.00 | 12.45 | -11,159,757 | ||
2023-12-20 |
|
4 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
S - Sale | -7,290,667 | 0 | -100.00 | 12.45 | -90,768,804 | ||
2023-12-20 |
|
4 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
S - Sale | -8,974,245 | 0 | -100.00 | 12.45 | -111,729,350 | ||
2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 16,143 | 548,938 | 3.03 | 5.38 | 86,909 | 2,955,318 | |
2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 125,909 | 4,308,573 | 3.01 | 5.38 | 677,856 | 23,196,064 | |
2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 153,693 | 5,309,432 | 2.98 | 5.38 | 827,437 | 28,584,389 | |
2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 47,712 | 532,795 | 9.84 | 5.00 | 238,555 | 2,663,922 | |
2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 390,507 | 4,182,664 | 10.30 | 5.00 | 1,952,496 | 20,912,902 | |
2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 493,337 | 5,155,739 | 10.58 | 5.00 | 2,466,636 | 25,778,179 | |
2023-11-13 | 3 | ENGN |
enGene Holdings Inc.
Class A Common Shares |
1,204,412 | ||||||||
2023-11-13 | 3 | ENGN |
enGene Holdings Inc.
Class A Common Shares |
912,776 | ||||||||
2023-11-13 | 3 | ENGN |
enGene Holdings Inc.
Class A Common Shares |
104,257 | ||||||||
2023-11-06 | 3 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
8,974,245 | ||||||||
2023-11-06 | 3 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
7,290,667 | ||||||||
2023-11-06 | 3 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
896,366 | ||||||||
2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 10,106 | 294,632 | 3.55 | 14.07 | 142,180 | 4,145,148 | |
2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 83,708 | 2,104,075 | 4.14 | 14.07 | 1,177,679 | 29,602,021 | |
2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 103,885 | 2,656,191 | 4.07 | 14.07 | 1,461,548 | 37,369,686 | |
2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 26,772 | 284,526 | 10.39 | 11.64 | 311,744 | 3,313,135 | |
2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 132,016 | 2,020,367 | 6.99 | 11.64 | 1,537,247 | 23,525,961 | |
2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 57,618 | 2,552,306 | 2.31 | 11.64 | 670,927 | 29,720,072 | |
2023-11-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 72,479 | 485,083 | 17.57 | 3.60 | 260,924 | 1,746,299 | |
2023-11-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 492,251 | 3,792,157 | 14.92 | 3.60 | 1,772,104 | 13,651,765 | |
2023-11-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 218,979 | 4,662,402 | 4.93 | 3.60 | 788,324 | 16,784,647 | |
2023-09-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
J - Other | 99,556 | 99,556 | |||||
2023-09-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 52,801 | 524,151 | 11.20 | 9.84 | 519,562 | 5,157,646 | |
2023-09-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 677,853 | 3,584,512 | 23.32 | 9.84 | 6,670,074 | 35,271,598 | |
2023-09-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 775,278 | 4,688,954 | 19.81 | 9.84 | 7,628,736 | 46,139,307 | |
2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -43,139 | 0 | -100.00 | 9.10 | -392,565 | ||
2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -1,526,147 | 0 | -100.00 | 9.10 | -13,887,938 | ||
2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -702,505 | 0 | -100.00 | 9.10 | -6,392,796 | ||
2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -2,595,239 | 0 | -100.00 | 9.10 | -23,616,675 | ||
2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -3,989,130 | 0 | -100.00 | 9.10 | -36,301,083 | ||
2023-05-22 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
11,007,420 | ||||||||
2023-05-22 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
8,581,171 | ||||||||
2023-05-22 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
744,966 | ||||||||
2023-05-12 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
J - Other | -462,605 | 0 | -100.00 | ||||
2023-05-12 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
J - Other | -2,929,660 | 0 | -100.00 | ||||
2023-05-12 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
J - Other | -4,018,253 | 0 | -100.00 | ||||
2023-05-09 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 86,341 | 145,029 | 147.12 | ||||
2023-05-09 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 837,146 | 1,812,558 | 85.82 | ||||
2023-05-09 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1,055,445 | 2,330,418 | 82.78 | ||||
2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
4,018,253 | ||||||||
2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
2,801,529 | ||||||||
2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
2,929,660 | ||||||||
2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
2,130,657 | ||||||||
2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
462,605 | ||||||||
2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
241,755 | ||||||||
2023-01-19 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
J - Other | -300,000 | 64,161 | -82.38 | ||||
2023-01-19 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
J - Other | -2,600,000 | 392,808 | -86.87 | ||||
2023-01-19 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
J - Other | -3,500,000 | 558,854 | -86.23 | ||||
2023-01-13 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 15,912 | 1,888,351 | 0.85 | 31.24 | 497,132 | 58,996,995 | |
2023-01-13 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 2,985 | 2,494,688 | 0.12 | 31.24 | 93,259 | 77,940,539 | |
2023-01-13 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 11,149 | 1,872,439 | 0.60 | 29.89 | 333,209 | 55,961,397 | |
2023-01-13 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 10,961 | 2,491,703 | 0.44 | 29.89 | 327,590 | 74,469,278 | |
2023-01-09 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1,573 | 1,618,637 | 0.10 | 21.98 | 34,577 | 35,580,393 | |
2023-01-09 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1,676 | 1,789,844 | 0.09 | 21.98 | 36,841 | 39,343,814 | |
2023-01-09 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 15,670 | 1,617,064 | 0.98 | 18.39 | 288,096 | 29,730,045 | |
2023-01-09 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,330 | 1,788,168 | 0.19 | 18.39 | 61,223 | 32,875,826 | |
2022-12-22 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
P - Purchase | 9,597 | 241,309 | 4.14 | 4.11 | 39,430 | 991,442 | |
2022-12-22 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
P - Purchase | 87,831 | 1,764,220 | 5.24 | 4.11 | 360,862 | 7,248,474 | |
2022-12-22 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
P - Purchase | 116,635 | 2,332,638 | 5.26 | 4.11 | 479,207 | 9,583,876 | |
2022-12-22 | 3 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
2,216,003 | ||||||||
2022-12-22 | 3 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
1,676,389 | ||||||||
2022-12-22 | 3 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
231,712 | ||||||||
2022-11-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
P - Purchase | 54,857 | 341,547 | 19.13 | 5.83 | 319,816 | 1,991,219 | |
2022-11-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
P - Purchase | 685,330 | 2,076,085 | 49.28 | 5.83 | 3,995,474 | 12,103,576 | |
2022-11-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
P - Purchase | 970,171 | 2,870,985 | 51.04 | 5.83 | 5,656,097 | 16,737,843 | |
2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 678 | 1,601,394 | 0.04 | 16.89 | 11,452 | 27,047,865 | |
2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1,004 | 1,784,838 | 0.06 | 16.89 | 16,958 | 30,146,271 | |
2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,021 | 1,600,716 | 0.19 | 16.83 | 50,849 | 26,942,771 | |
2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,339 | 1,783,834 | 0.19 | 16.83 | 56,201 | 30,024,959 | |
2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9,885 | 1,597,695 | 0.62 | 16.50 | 163,073 | 26,357,174 | |
2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 6,715 | 1,780,495 | 0.38 | 16.50 | 110,777 | 29,372,826 | |
2022-09-16 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 13,396 | 1,773,780 | 0.76 | 17.89 | 239,618 | 31,728,135 | |
2022-09-16 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10,897 | 1,587,810 | 0.69 | 17.89 | 194,918 | 28,401,634 | |
2022-09-16 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 5,575 | 1,576,913 | 0.35 | 17.96 | 100,138 | 28,324,511 | |
2022-09-16 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 26,441 | 1,571,338 | 1.71 | 17.25 | 456,044 | 27,101,809 | |
2022-08-23 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 27,117 | 257,754 | 11.76 | 26.00 | 705,042 | 6,701,604 | |
2022-08-23 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 233,362 | 1,861,290 | 14.33 | 26.00 | 6,067,412 | 48,393,540 | |
2022-08-23 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 285,046 | 2,480,742 | 12.98 | 26.00 | 7,411,196 | 64,499,292 | |
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
C - Conversion | 1,519,999 | 1,526,147 | 24,723.47 | ||||
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
S - Sale | -1,289,434 | 6,148 | -99.53 | 6.12 | -7,891,336 | 37,626 | |
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
C - Conversion | 682,666 | 702,505 | 3,441.03 | ||||
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
S - Sale | -469,040 | 19,839 | -95.94 | 6.12 | -2,870,525 | 121,415 | |
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
C - Conversion | 2,426,666 | 2,595,239 | 1,439.53 | ||||
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
S - Sale | -2,890,723 | 168,573 | -94.49 | 6.12 | -17,691,225 | 1,031,667 | |
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
C - Conversion | 3,754,000 | 3,989,130 | 1,596.56 | ||||
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
S - Sale | -3,850,803 | 235,130 | -94.25 | 6.12 | -23,566,914 | 1,438,996 | |
2022-07-21 | 3 | EPIX |
ESSA Pharma Inc.
Common Stock |
4,712,590 | ||||||||
2022-07-21 | 3 | EPIX |
ESSA Pharma Inc.
Common Stock |
3,491,779 | ||||||||
2022-07-21 | 3 | EPIX |
ESSA Pharma Inc.
Common Stock |
357,472 | ||||||||
2022-06-27 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock |
2,132,411 | ||||||||
2022-06-27 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock |
1,570,857 | ||||||||
2022-06-27 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock |
209,716 | ||||||||
2022-06-15 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 6,168 | 412,604 | 1.52 | 12.73 | 78,519 | 5,252,449 | |
2022-06-15 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 68,327 | 3,299,906 | 2.11 | 12.73 | 869,803 | 42,007,803 | |
2022-06-15 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 74,666 | 4,443,423 | 1.71 | 12.73 | 950,498 | 56,564,775 | |
2022-06-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 41,417 | 2,906,659 | 1.45 | 4.03 | 167,097 | 11,726,916 | |
2022-06-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 158,583 | 3,913,676 | 4.22 | 4.03 | 639,803 | 15,789,726 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 20 | 406,436 | 0.00 | 13.21 | 264 | 5,369,751 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 3,040 | 3,231,579 | 0.09 | 13.21 | 40,164 | 42,694,975 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 3,809 | 4,368,757 | 0.09 | 13.21 | 50,324 | 57,719,144 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 31,903 | 406,416 | 8.52 | 12.29 | 391,960 | 4,993,227 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 258,797 | 3,228,539 | 8.71 | 12.29 | 3,179,580 | 39,665,830 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 353,344 | 4,364,948 | 8.81 | 12.29 | 4,341,184 | 53,627,751 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 61,156 | 374,513 | 19.52 | 11.68 | 714,449 | 4,375,211 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 464,235 | 2,969,742 | 18.53 | 11.68 | 5,423,379 | 34,693,714 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 660,654 | 4,011,604 | 19.72 | 11.68 | 7,718,024 | 46,865,163 | |
2022-06-03 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 44,746 | 364,161 | 14.01 | 11.00 | 492,179 | 4,005,553 | |
2022-06-03 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 301,009 | 2,992,808 | 11.18 | 11.00 | 3,310,918 | 32,919,092 | |
2022-06-03 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 405,641 | 4,058,854 | 11.10 | 11.00 | 4,461,808 | 44,644,959 | |
2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 3,223 | 230,637 | 1.42 | 14.78 | 47,645 | 3,409,461 | |
2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 26,353 | 1,627,928 | 1.65 | 14.78 | 389,571 | 24,065,334 | |
2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 35,793 | 2,195,696 | 1.66 | 14.78 | 529,121 | 32,458,535 | |
2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 10,642 | 227,414 | 4.91 | 14.21 | 151,229 | 3,231,689 | |
2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 90,372 | 1,601,575 | 5.98 | 14.21 | 1,284,240 | 22,759,342 | |
2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 123,043 | 2,159,903 | 6.04 | 14.21 | 1,748,515 | 30,693,518 | |
2022-05-24 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 37 | 216,772 | 0.02 | 14.00 | 518 | 3,034,678 | |
2022-05-24 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 4,180 | 1,511,203 | 0.28 | 14.00 | 58,517 | 21,155,935 | |
2022-05-24 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 5,883 | 2,036,860 | 0.29 | 14.00 | 82,358 | 28,514,818 | |
2022-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 5,730 | 313,357 | 1.86 | 8.50 | 48,705 | 2,663,534 | |
2022-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 189,882 | 2,505,507 | 8.20 | 8.50 | 1,613,997 | 21,296,810 | |
2022-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 224,388 | 3,350,950 | 7.18 | 8.50 | 1,907,298 | 28,483,075 | |
2022-05-20 |
|
4 | XOMA |
XOMA Corp
Non-Qualified Stock Option (right to buy) |
A - Award | 8,996 | 8,996 | |||||
2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 17,744 | 319,415 | 5.88 | 9.14 | 162,091 | 2,917,856 | |
2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 38,558 | 2,691,799 | 1.45 | 9.14 | 352,227 | 24,589,584 | |
2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 53,598 | 3,653,213 | 1.49 | 9.14 | 489,618 | 33,372,101 | |
2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 457,001 | 2,653,241 | 20.81 | 9.06 | 4,140,429 | 24,038,363 | |
2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 542,999 | 3,599,615 | 17.76 | 9.06 | 4,919,571 | 32,612,512 | |
2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 4,131 | 216,735 | 1.94 | 19.26 | 79,542 | 4,173,232 | |
2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 40,659 | 1,507,023 | 2.77 | 19.26 | 782,889 | 29,017,728 | |
2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 55,210 | 2,030,977 | 2.79 | 19.26 | 1,063,069 | 39,106,462 | |
2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 4,066 | 212,604 | 1.95 | 19.60 | 79,690 | 4,166,847 | |
2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 70,439 | 1,466,364 | 5.05 | 19.60 | 1,380,541 | 28,739,415 | |
2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 75,495 | 1,975,767 | 3.97 | 19.60 | 1,479,634 | 38,723,255 | |
2022-04-15 | 3 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
11,265,678 | ||||||||
2022-04-15 | 3 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
9,005,699 | ||||||||
2022-04-15 | 3 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
1,420,317 | ||||||||
2022-04-05 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 9,402 | 2,196,240 | 0.43 | 10.75 | 101,071 | 23,609,360 | |
2022-04-05 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 266,598 | 3,056,616 | 9.56 | 10.75 | 2,865,902 | 32,858,316 | |
2022-03-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Stock Option (Right to Buy) |
A - Award | 80,000 | 80,000 | |||||
2022-02-07 | 3 | VSTM |
Verastem, Inc.
Common Stock |
10,753,294 | ||||||||
2022-02-07 | 3 | VSTM |
Verastem, Inc.
Common Stock |
7,883,287 | ||||||||
2022-02-07 | 3 | VSTM |
Verastem, Inc.
Common Stock |
994,353 | ||||||||
2022-01-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 14,323 | 1,395,925 | 1.04 | 40.70 | 582,946 | 56,814,148 | |
2022-01-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 20,085 | 1,900,272 | 1.07 | 40.70 | 817,460 | 77,341,070 | |
2022-01-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 37,859 | 1,381,602 | 2.82 | 38.33 | 1,451,207 | 52,959,430 | |
2022-01-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 58,042 | 1,880,187 | 3.19 | 38.33 | 2,224,860 | 72,071,140 | |
2022-01-31 | 3 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
1,274,973 | ||||||||
2022-01-31 | 3 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
975,412 | ||||||||
2022-01-31 | 3 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
58,688 | ||||||||
2022-01-26 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 114,726 | 1,343,743 | 9.33 | 37.76 | 4,332,455 | 50,744,439 | |
2022-01-26 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 158,041 | 1,822,145 | 9.50 | 37.76 | 5,968,181 | 68,810,573 | |
2022-01-21 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 7,899 | 307,627 | 2.64 | 14.10 | 111,376 | 4,337,541 | |
2022-01-21 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 412,264 | 2,315,625 | 21.66 | 14.10 | 5,812,922 | 32,650,312 | |
2022-01-21 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 577,798 | 3,126,562 | 22.67 | 14.10 | 8,146,952 | 44,084,524 | |
2022-01-10 | 3 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
2,790,018 | ||||||||
2022-01-10 | 3 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
2,186,838 | ||||||||
2022-01-10 | 3 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
301,671 | ||||||||
2022-01-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 14,806 | 185,388 | 8.68 | 12.00 | 177,672 | 2,224,656 | |
2022-01-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 226,079 | 1,367,838 | 19.80 | 12.00 | 2,712,948 | 16,414,056 | |
2022-01-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 255,500 | 1,734,960 | 17.27 | 12.00 | 3,066,000 | 20,819,520 | |
2022-01-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 61,343 | 1,141,759 | 5.68 | 12.00 | 736,018 | 13,699,281 | |
2021-12-02 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 35,268 | 471,350 | 8.09 | 9.39 | 331,177 | 4,426,118 | |
2021-12-02 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 341,977 | 2,865,242 | 13.55 | 9.39 | 3,211,267 | 26,905,482 | |
2021-12-02 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 362,430 | 3,755,093 | 10.68 | 9.39 | 3,403,326 | 35,261,450 | |
2021-11-08 | 3 | RPTX |
Repare Therapeutics Inc.
Common Stock |
2,548,764 | ||||||||
2021-11-08 | 3 | RPTX |
Repare Therapeutics Inc.
Common Stock |
1,903,361 | ||||||||
2021-11-08 | 3 | RPTX |
Repare Therapeutics Inc.
Common Stock |
299,728 | ||||||||
2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -8,929 | 232,747 | -3.69 | 27.79 | -248,106 | 6,467,225 | |
2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -58,327 | 1,520,405 | -3.69 | 27.79 | -1,620,703 | 42,246,734 | |
2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -80,011 | 2,085,664 | -3.69 | 27.79 | -2,223,226 | 57,953,303 | |
2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -69,534 | 241,676 | -22.34 | 27.53 | -1,914,348 | 6,653,606 | |
2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -384,914 | 1,578,732 | -19.60 | 27.53 | -10,597,106 | 43,464,229 | |
2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -530,999 | 2,165,675 | -19.69 | 27.53 | -14,618,987 | 59,623,415 | |
2021-09-23 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 590 | 170,582 | 0.35 | 13.94 | 8,226 | 2,378,357 | |
2021-09-23 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 4,102 | 1,080,416 | 0.38 | 13.94 | 57,193 | 15,063,808 | |
2021-09-23 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,341 | 1,479,460 | 0.43 | 13.94 | 88,410 | 20,627,519 | |
2021-09-15 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 20,512 | 169,992 | 13.72 | 16.49 | 338,243 | 2,803,168 | |
2021-09-15 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 158,511 | 1,076,314 | 17.27 | 16.49 | 2,613,846 | 17,748,418 | |
2021-09-15 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 213,246 | 1,473,119 | 16.93 | 16.49 | 3,516,427 | 24,291,732 | |
2021-07-07 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -150,805 | 311,210 | -32.64 | 20.75 | -3,129,204 | 6,457,608 | |
2021-07-07 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -928,739 | 1,963,646 | -32.11 | 20.75 | -19,271,334 | 40,745,654 | |
2021-07-07 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -1,106,478 | 2,696,674 | -29.09 | 20.75 | -22,959,418 | 55,955,986 | |
2021-07-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 27,458 | 208,538 | 15.16 | 47.00 | 1,290,526 | 9,801,286 | |
2021-07-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 211,711 | 1,229,017 | 20.81 | 47.00 | 9,950,417 | 57,763,799 | |
2021-07-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 304,997 | 1,664,104 | 22.44 | 47.00 | 14,334,859 | 78,212,888 | |
2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 16,980 | 149,480 | 12.82 | 15.25 | 258,945 | 2,279,570 | |
2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 106,627 | 917,803 | 13.14 | 15.25 | 1,626,062 | 13,996,496 | |
2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 146,116 | 1,259,873 | 13.12 | 15.25 | 2,228,269 | 19,213,063 | |
2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 20,018 | 132,500 | 17.80 | 15.65 | 313,282 | 2,073,625 | |
2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 124,804 | 811,176 | 18.18 | 15.65 | 1,953,183 | 12,694,904 | |
2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 172,457 | 1,113,757 | 18.32 | 15.65 | 2,698,952 | 17,430,297 | |
2021-06-21 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 20,063 | 20,063 | |||||
2021-05-26 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
J - Other | 99,556 | 99,556 | |||||
2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 129 | 112,482 | 0.11 | 15.90 | 2,050 | 1,787,924 | |
2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 513 | 686,372 | 0.07 | 15.90 | 8,154 | 10,910,020 | |
2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 719 | 941,300 | 0.08 | 15.90 | 11,429 | 14,962,152 | |
2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 7,592 | 112,353 | 7.25 | 15.94 | 121,032 | 1,791,132 | |
2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 48,152 | 685,859 | 7.55 | 15.94 | 767,639 | 10,933,964 | |
2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 66,242 | 940,581 | 7.58 | 15.94 | 1,056,030 | 14,994,742 | |
2021-05-21 |
|
4 | XOMA |
XOMA Corp
Non-Qualified Stock Option (right to buy) |
A - Award | 5,101 | 5,101 | |||||
2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 1,115 | 104,761 | 1.08 | 15.88 | 17,711 | 1,664,055 | |
2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,962 | 637,707 | 1.10 | 15.88 | 110,586 | 10,129,529 | |
2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 9,191 | 874,339 | 1.06 | 15.88 | 145,993 | 13,888,263 | |
2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 11,946 | 103,646 | 13.03 | 16.65 | 198,901 | 1,725,706 | |
2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 75,640 | 630,745 | 13.63 | 16.65 | 1,259,406 | 10,501,904 | |
2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 103,611 | 865,148 | 13.61 | 16.65 | 1,725,123 | 14,404,714 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 1,747 | 88,226 | 2.02 | 14.90 | 26,032 | 1,314,647 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 10,876 | 532,384 | 2.09 | 14.90 | 162,062 | 7,933,001 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 14,790 | 729,732 | 2.07 | 14.90 | 220,384 | 10,873,664 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,141 | 86,479 | 7.64 | 15.93 | 97,817 | 1,377,481 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 62,948 | 80,338 | 361.98 | 17.00 | 1,070,116 | 1,365,746 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 38,858 | 521,508 | 8.05 | 15.93 | 618,950 | 8,306,840 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 398,300 | 482,650 | 472.20 | 17.00 | 6,771,100 | 8,205,050 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 53,303 | 714,942 | 8.06 | 15.93 | 849,037 | 11,387,954 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 546,346 | 661,639 | 473.88 | 17.00 | 9,287,882 | 11,247,863 | |
2021-05-17 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 3,474 | 91,700 | 3.94 | 14.26 | 49,544 | 1,307,780 | |
2021-05-17 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 22,721 | 555,105 | 4.27 | 14.26 | 324,036 | 7,916,630 | |
2021-05-17 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 31,805 | 761,537 | 4.36 | 14.26 | 453,587 | 10,860,660 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 1,747 | 88,226 | 2.02 | 14.90 | 26,032 | 1,314,647 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 10,876 | 532,384 | 2.09 | 14.90 | 162,062 | 7,933,001 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 14,790 | 729,732 | 2.07 | 14.90 | 220,384 | 10,873,664 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -134,515 | 0 | -100.00 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -152,176 | 0 | -100.00 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -17,390 | 152,176 | -10.26 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -837,397 | 0 | -100.00 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -553,359 | 0 | -100.00 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -84,350 | 553,359 | -13.23 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1,068,554 | 0 | -100.00 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -832,261 | 0 | -100.00 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -115,293 | 832,261 | -12.17 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 134,515 | 286,691 | 88.39 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 152,176 | 152,176 | |||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 6,141 | 86,479 | 7.64 | 15.93 | 97,817 | 1,377,481 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 62,948 | 80,338 | 361.98 | 17.00 | 1,070,116 | 1,365,746 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
C - Conversion | 17,390 | 17,390 | |||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 837,397 | 1,390,756 | 151.33 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 553,359 | 553,359 | |||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 38,858 | 521,508 | 8.05 | 15.93 | 618,950 | 8,306,840 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 398,300 | 482,650 | 472.20 | 17.00 | 6,771,100 | 8,205,050 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
C - Conversion | 84,350 | 84,350 | |||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 1,068,554 | 1,900,815 | 128.39 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 832,261 | 832,261 | |||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 53,303 | 714,942 | 8.06 | 15.93 | 849,037 | 11,387,954 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 546,346 | 661,639 | 473.88 | 17.00 | 9,287,882 | 11,247,863 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
C - Conversion | 115,293 | 115,293 | |||||
2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X1 Convertible Preferred Stock |
P - Purchase | 17 | 17 | 25,000.00 | 425,000 | 425,000 | ||
2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X1 Convertible Preferred Stock |
P - Purchase | 239 | 239 | 25,000.00 | 5,975,000 | 5,975,000 | ||
2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X1 Convertible Preferred Stock |
P - Purchase | 344 | 344 | 25,000.00 | 8,600,000 | 8,600,000 | ||
2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 5,171 | 488,879 | 1.07 | 2.50 | 12,928 | 1,222,198 | |
2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 950,016 | 3,059,296 | 45.04 | 2.50 | 2,375,040 | 7,648,240 | |
2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 1,044,813 | 4,085,933 | 34.36 | 2.50 | 2,612,032 | 10,214,832 | |
2021-04-02 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
S - Sale | -81,903 | 149,975 | -35.32 | 38.36 | -3,141,799 | 5,753,041 | |
2021-04-02 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
S - Sale | -84,250 | 75,287 | -52.81 | 38.36 | -3,231,830 | 2,888,009 | |
2021-04-02 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
S - Sale | -205,807 | 1,544,897 | -11.76 | 38.36 | -7,894,757 | 59,262,249 | |
2021-04-02 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
S - Sale | -279,740 | 1,760,384 | -13.71 | 38.36 | -10,730,826 | 67,528,330 | |
2021-04-01 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 26,894 | 462,015 | 6.18 | 19.75 | 531,156 | 9,124,796 | |
2021-04-01 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 108,106 | 2,892,385 | 3.88 | 19.75 | 2,135,094 | 57,124,604 | |
2021-04-01 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 165,000 | 3,803,152 | 4.54 | 19.75 | 3,258,750 | 75,112,252 | |
2021-03-24 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 7,744 | 435,121 | 1.81 | 22.75 | 176,176 | 9,899,003 | |
2021-03-24 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 71,756 | 3,638,152 | 2.01 | 22.75 | 1,632,449 | 82,767,958 | |
2021-03-18 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 1,171 | 427,377 | 0.27 | 23.00 | 26,933 | 9,829,500 | |
2021-03-18 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 195,768 | 2,784,279 | 7.56 | 23.00 | 4,502,586 | 64,037,303 | |
2021-03-18 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 53,061 | 3,566,396 | 1.51 | 23.00 | 1,220,382 | 82,025,681 | |
2021-03-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Stock Option (Right to Buy) |
A - Award | 80,000 | 80,000 | |||||
2021-03-08 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value per share |
3,372,098 | ||||||||
2021-03-08 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value per share |
2,484,643 | ||||||||
2021-03-08 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value per share |
405,344 | ||||||||
2021-02-16 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -152,127 | 534,847 | -22.14 | 5.37 | -816,709 | 2,871,380 | |
2021-02-16 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -892,467 | 3,279,831 | -21.39 | 5.37 | -4,791,298 | 17,608,101 | |
2021-02-16 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -1,215,491 | 4,448,421 | -21.46 | 5.37 | -6,525,485 | 23,881,793 | |
2021-02-04 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -4,325 | 233,150 | -1.82 | 18.00 | -77,850 | 4,196,700 | |
2021-02-04 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -16,850 | 1,188,131 | -1.40 | 18.00 | -303,300 | 21,386,358 | |
2021-02-04 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -25,234 | 1,642,186 | -1.51 | 18.00 | -454,212 | 29,559,348 | |
2021-01-26 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -568,019 | 686,974 | -45.26 | 4.14 | -2,350,917 | 2,843,248 | |
2021-01-26 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -2,458,838 | 4,172,298 | -37.08 | 4.14 | -10,176,639 | 17,268,307 | |
2021-01-26 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -2,821,663 | 5,663,912 | -33.25 | 4.14 | -11,678,299 | 23,441,799 | |
2021-01-25 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 43,422 | 426,206 | 11.34 | 24.75 | 1,074,694 | 10,548,598 | |
2021-01-25 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 343,444 | 2,588,511 | 15.30 | 24.75 | 8,500,239 | 64,065,647 | |
2021-01-25 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 457,814 | 3,513,335 | 14.98 | 24.75 | 11,330,896 | 86,955,041 | |
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X1 Convertible Preferred Stock |
C - Conversion | -1,757 | 6,758 | -20.63 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X1 Convertible Preferred Stock |
C - Conversion | -9,169 | 39,693 | -18.77 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X1 Convertible Preferred Stock |
C - Conversion | -11,776 | 52,145 | -18.42 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X Convertible Preferred |
C - Conversion | -35 | 0 | -100.00 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X Convertible Preferred |
C - Conversion | -203 | 0 | -100.00 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X Convertible Preferred |
C - Conversion | -273 | 0 | -100.00 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 97,615 | 113,152 | 628.27 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 1,944 | 15,537 | 14.30 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 509,410 | 598,624 | 571.00 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 11,278 | 89,214 | 14.47 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 654,215 | 771,780 | 556.47 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 15,166 | 117,565 | 14.81 | ||||
2020-12-28 | 3 | CTMX |
CytomX Therapeutics, Inc.
Common Stock, $0.00001 par value per share |
2,945,743 | ||||||||
2020-12-28 | 3 | CTMX |
CytomX Therapeutics, Inc.
Common Stock, $0.00001 par value per share |
2,164,406 | ||||||||
2020-12-28 | 3 | CTMX |
CytomX Therapeutics, Inc.
Common Stock, $0.00001 par value per share |
358,450 | ||||||||
2020-12-22 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 45,032 | 2,245,067 | 2.05 | 16.05 | 722,764 | 36,033,325 | |
2020-12-22 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 114,968 | 3,055,521 | 3.91 | 16.05 | 1,845,236 | 49,041,112 | |
2020-12-15 |
|
4 | XOMA |
XOMA Corp
8.625% Series A Cumulative Perpetual Preferred Stock |
P - Purchase | 200,000 | 200,000 | 25.00 | 5,000,000 | 5,000,000 | ||
2020-12-11 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -25,486 | 463,244 | -5.21 | 18.00 | -458,748 | 8,338,392 | |
2020-12-11 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -166,194 | 2,760,185 | -5.68 | 18.00 | -2,991,492 | 49,683,330 | |
2020-12-11 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -239,274 | 3,811,271 | -5.91 | 18.00 | -4,306,932 | 68,602,878 | |
2020-12-04 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
4,050,545 | ||||||||
2020-12-04 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
2,926,379 | ||||||||
2020-12-04 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
488,730 | ||||||||
2020-11-20 |
|
4 | CYTK |
CYTOKINETICS INC
Call Option |
J - Other | -93 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | CYTK |
CYTOKINETICS INC
Call Option |
J - Other | -551 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | CYTK |
CYTOKINETICS INC
Call Option |
J - Other | -740 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -73,399 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -522,403 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -760,155 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -101,784 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -673,281 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -889,186 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -185,908 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -881,156 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -1,129,404 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 74,991 | 436,082 | 20.77 | 19.00 | 1,424,829 | 8,285,558 | |
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 73,399 | 361,091 | 25.51 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 101,784 | 287,692 | 54.75 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 185,908 | 185,908 | |||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 446,425 | 2,523,265 | 21.50 | 19.00 | 8,482,075 | 47,942,035 | |
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 522,403 | 2,076,840 | 33.61 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 673,281 | 1,554,437 | 76.41 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 881,156 | 881,156 | |||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 613,918 | 3,392,663 | 22.09 | 19.00 | 11,664,442 | 64,460,597 | |
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 760,155 | 2,778,745 | 37.66 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 889,186 | 2,018,590 | 78.73 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 1,129,404 | 1,129,404 | |||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Stock Option (Right to buy) |
A - Award | 21,520 | 21,520 | |||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Stock Option (Right to buy) |
A - Award | 21,520 | 21,520 | |||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Stock Option (Right to buy) |
A - Award | 21,520 | 21,520 | |||||
2020-11-16 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
3,822,766 | ||||||||
2020-11-16 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
2,777,320 | ||||||||
2020-11-16 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
465,924 | ||||||||
2020-11-13 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
S - Sale | -502,649 | 81,263 | -86.08 | 20.19 | -10,146,825 | 1,640,432 | |
2020-11-13 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
S - Sale | -2,949,477 | 485,513 | -85.87 | 20.19 | -59,540,207 | 9,800,905 | |
2020-11-13 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
S - Sale | -3,941,214 | 670,695 | -85.46 | 20.19 | -79,560,105 | 13,539,119 | |
2020-11-06 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 86,090 | 630,453 | 15.81 | 2.60 | 223,834 | 1,639,178 | |
2020-11-06 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 506,155 | 3,712,350 | 15.79 | 2.60 | 1,316,003 | 9,652,110 | |
2020-11-06 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 674,492 | 4,980,812 | 15.66 | 2.60 | 1,753,679 | 12,950,111 | |
2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2,334 | 583,912 | 0.40 | 4.98 | 11,633 | 2,910,217 | |
2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 10,436 | 3,434,990 | 0.30 | 4.98 | 52,013 | 17,119,990 | |
2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 17,230 | 4,611,909 | 0.37 | 4.98 | 85,874 | 22,985,754 | |
2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 15,355 | 581,578 | 2.71 | 4.88 | 74,997 | 2,840,543 | |
2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 143,403 | 3,424,554 | 4.37 | 4.88 | 700,409 | 16,726,207 | |
2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 257,804 | 4,594,679 | 5.94 | 4.88 | 1,259,166 | 22,441,331 | |
2020-11-03 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 15,472 | 544,363 | 2.93 | 2.75 | 42,548 | 1,496,998 | |
2020-11-03 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 250,755 | 3,206,195 | 8.48 | 2.75 | 689,576 | 8,817,036 | |
2020-11-03 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 666,385 | 4,306,320 | 18.31 | 2.75 | 1,832,559 | 11,842,380 | |
2020-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 25,107 | 566,223 | 4.64 | 5.04 | 126,414 | 2,850,933 | |
2020-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 162,352 | 3,281,151 | 5.21 | 5.04 | 817,442 | 16,520,595 | |
2020-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 157,782 | 4,336,875 | 3.78 | 5.04 | 794,432 | 21,836,166 | |
2020-10-05 | 3 | NVUS |
Novus Therapeutics, Inc.
Common Stock |
102,400 | ||||||||
2020-10-05 | 3 | NVUS |
Novus Therapeutics, Inc.
Common Stock |
77,936 | ||||||||
2020-10-05 | 3 | NVUS |
Novus Therapeutics, Inc.
Common Stock |
13,595 | ||||||||
2020-09-24 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 32 | 541,116 | 0.01 | 3.80 | 122 | 2,055,537 | |
2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 7,201 | 1,750,704 | 0.41 | 18.20 | 131,057 | 31,862,463 | |
2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9,888 | 2,040,124 | 0.49 | 18.20 | 179,960 | 37,129,849 | |
2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4,991 | 1,743,503 | 0.29 | 18.45 | 92,062 | 32,160,133 | |
2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 6,960 | 2,030,236 | 0.34 | 18.45 | 128,382 | 37,449,124 | |
2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10,069 | 1,738,512 | 0.58 | 18.39 | 185,120 | 31,962,717 | |
2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 12,259 | 2,023,276 | 0.61 | 18.39 | 225,383 | 37,198,132 | |
2020-09-17 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 10,258 | 382,784 | 2.75 | 11.75 | 120,532 | 4,497,712 | |
2020-09-17 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 58,745 | 2,200,035 | 2.74 | 11.75 | 690,254 | 25,850,411 | |
2020-09-17 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 77,751 | 2,940,553 | 2.72 | 11.75 | 913,574 | 34,551,498 | |
2020-09-14 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 12,816 | 372,526 | 3.56 | 11.10 | 142,235 | 4,134,368 | |
2020-09-14 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 76,374 | 2,141,290 | 3.70 | 11.10 | 847,614 | 23,764,465 | |
2020-09-14 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 100,461 | 2,862,802 | 3.64 | 11.10 | 1,114,936 | 31,771,949 | |
2020-09-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,830 | 1,728,443 | 0.22 | 18.77 | 71,891 | 32,443,912 | |
2020-09-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,907 | 2,011,017 | 0.19 | 18.77 | 73,337 | 37,747,996 | |
2020-09-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 14,339 | 359,710 | 4.15 | 11.17 | 160,167 | 4,017,961 | |
2020-09-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 82,740 | 2,064,916 | 4.17 | 11.17 | 924,206 | 23,065,112 | |
2020-09-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 104,827 | 2,762,341 | 3.94 | 11.17 | 1,170,918 | 30,855,349 | |
2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 7,672 | 1,724,613 | 0.45 | 18.87 | 144,741 | 32,536,721 | |
2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9,900 | 2,007,110 | 0.50 | 18.87 | 186,774 | 37,866,338 | |
2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 6,862 | 1,716,941 | 0.40 | 18.48 | 126,814 | 31,730,100 | |
2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9,143 | 1,997,210 | 0.46 | 18.48 | 168,968 | 36,909,639 | |
2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 922 | 1,710,079 | 0.05 | 19.17 | 17,676 | 32,785,464 | |
2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1,122 | 1,988,067 | 0.06 | 19.17 | 21,511 | 38,115,022 | |
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -180,686 | 0 | -100.00 | ||||
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -1,000,955 | 0 | -100.00 | ||||
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -1,336,390 | 0 | -100.00 | ||||
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 67,791 | 181,081 | 59.84 | 20.00 | 1,355,820 | 3,621,620 | |
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 113,290 | 113,290 | |||||
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 389,709 | 1,017,307 | 62.10 | 20.00 | 7,794,180 | 20,346,140 | |
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 627,598 | 627,598 | |||||
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 521,193 | 1,359,109 | 62.20 | 20.00 | 10,423,860 | 27,182,180 | |
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 837,916 | 837,916 | |||||
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | -40,127 | 40,127 | -50.00 | ||||
2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 2,244 | 1,709,157 | 0.13 | 19.74 | 44,308 | 33,747,305 | |
2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,443 | 1,986,945 | 0.17 | 19.74 | 67,982 | 39,232,229 | |
2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 5,179 | 1,706,913 | 0.30 | 19.31 | 100,003 | 32,959,295 | |
2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 6,504 | 1,983,502 | 0.33 | 19.31 | 125,588 | 38,300,035 | |
2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1,607 | 1,701,734 | 0.09 | 19.32 | 31,050 | 32,880,224 | |
2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9,198 | 1,976,998 | 0.47 | 19.32 | 177,720 | 38,198,765 | |
2020-08-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Call Option (Right to Buy) |
P - Purchase | 158 | 3,547 | 4.66 | 35.79 | 5,655 | 126,947 | |
2020-08-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Call Option (Right to Buy) |
P - Purchase | 905 | 20,390 | 4.64 | 35.79 | 32,390 | 729,758 | |
2020-08-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Call Option (Right to Buy) |
P - Purchase | 1,205 | 27,265 | 4.62 | 35.79 | 43,127 | 975,814 | |
2020-08-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1,772 | 1,967,800 | 0.09 | 19.12 | 33,881 | 37,624,336 | |
2020-08-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,496 | 1,966,028 | 0.18 | 19.70 | 68,877 | 38,733,897 | |
2020-08-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 895 | 1,962,532 | 0.05 | 19.27 | 17,246 | 37,816,814 | |
2020-08-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 21,922 | 1,961,637 | 1.13 | 18.69 | 409,810 | 36,670,842 | |
2020-08-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1,050 | 1,939,715 | 0.05 | 17.80 | 18,693 | 34,533,134 | |
2020-08-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4,050 | 1,938,665 | 0.21 | 17.34 | 70,233 | 33,619,359 | |
2020-07-02 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 81 | 237,475 | 0.03 | 13.32 | 1,079 | 3,162,312 | |
2020-07-02 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 929 | 1,204,981 | 0.08 | 13.32 | 12,371 | 16,046,009 | |
2020-07-02 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 1,521 | 1,667,420 | 0.09 | 13.32 | 20,254 | 22,204,032 | |
2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 1,354 | 237,394 | 0.57 | 13.93 | 18,868 | 3,308,014 | |
2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 7,854 | 1,204,052 | 0.66 | 13.93 | 109,443 | 16,778,103 | |
2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 10,524 | 1,665,899 | 0.64 | 13.93 | 146,649 | 23,213,803 | |
2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 6,769 | 236,040 | 2.95 | 14.39 | 97,403 | 3,396,498 | |
2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 39,052 | 1,196,198 | 3.37 | 14.39 | 561,939 | 17,212,691 | |
2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 52,443 | 1,655,375 | 3.27 | 14.39 | 754,629 | 23,820,019 | |
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-10 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 6,967 | 345,371 | 2.06 | 15.20 | 105,898 | 5,249,639 | |
2020-06-10 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 33,321 | 1,982,176 | 1.71 | 15.20 | 506,479 | 30,129,075 | |
2020-06-10 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 46,966 | 2,657,514 | 1.80 | 15.20 | 713,883 | 40,394,213 | |
2020-06-03 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 94,101 | 338,404 | 38.52 | 14.00 | 1,317,414 | 4,737,656 | |
2020-06-03 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 561,966 | 1,948,855 | 40.52 | 14.00 | 7,867,524 | 27,283,970 | |
2020-06-03 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 806,443 | 2,610,548 | 44.70 | 14.00 | 11,290,202 | 36,547,672 | |
2020-05-26 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -192,250 | 480,432 | -28.58 | 6.00 | -1,153,500 | 2,882,592 | |
2020-05-26 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -1,064,332 | 2,766,561 | -27.78 | 6.00 | -6,385,992 | 16,599,366 | |
2020-05-26 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -1,027,016 | 3,712,340 | -21.67 | 6.00 | -6,162,096 | 22,274,040 | |
2020-05-18 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 4,476 | 541,084 | 0.83 | 4.10 | 18,352 | 2,218,444 | |
2020-05-18 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 39,810 | 3,118,799 | 1.29 | 4.10 | 163,221 | 12,787,076 | |
2020-05-18 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 249,301 | 4,179,093 | 6.34 | 4.10 | 1,022,134 | 17,134,281 | |
2020-04-17 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
C - Conversion | -597 | 0 | -100.00 | ||||
2020-04-17 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
C - Conversion | -656 | 0 | -100.00 | ||||
2020-04-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
C - Conversion | 596,813 | 1,700,127 | 54.09 | 13.00 | 7,758,569 | 22,101,651 | |
2020-04-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
C - Conversion | 655,959 | 1,934,615 | 51.30 | 13.00 | 8,527,467 | 25,149,995 | |
2020-03-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 8,264 | 1,278,656 | 0.65 | 17.20 | 142,129 | 21,991,093 | |
2020-03-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4,439 | 1,270,392 | 0.35 | 14.52 | 64,475 | 18,451,936 | |
2020-03-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 8,113 | 1,265,953 | 0.64 | 15.73 | 127,648 | 19,918,125 | |
2020-03-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10,164 | 1,257,840 | 0.81 | 15.73 | 159,916 | 19,790,351 | |
2020-03-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 100,000 | 1,247,676 | 8.71 | 18.34 | 1,834,090 | 22,883,501 | |
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
P - Purchase | 12 | 12 | |||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
P - Purchase | 87 | 191 | 83.65 | ||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
P - Purchase | 841 | 1,250 | 205.62 | ||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
P - Purchase | 981 | 1,594 | 160.03 | ||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
X - Other | 104 | 104 | |||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Subscription Rights (right to buy) |
X - Other | -104 | 0 | -100.00 | ||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
X - Other | 409 | 409 | |||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Subscription Rights (right to buy) |
X - Other | -409 | 0 | -100.00 | ||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
X - Other | 613 | 613 | |||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Subscription Rights (right to buy) |
X - Other | -613 | 0 | -100.00 | ||||
2020-02-18 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -74,893 | 424,419 | -15.00 | 15.79 | -1,182,321 | 6,700,218 | |
2020-02-18 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -510,793 | 2,350,829 | -17.85 | 15.79 | -8,063,787 | 37,112,067 | |
2020-02-18 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -486,344 | 3,131,432 | -13.44 | 15.79 | -7,677,815 | 49,435,291 | |
2020-01-21 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 19,727 | 244,303 | 8.78 | 16.15 | 318,591 | 3,945,493 | |
2020-01-21 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 112,561 | 1,386,889 | 8.83 | 16.15 | 1,817,860 | 22,398,257 | |
2020-01-21 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 146,442 | 1,804,105 | 8.83 | 16.15 | 2,365,038 | 29,136,296 | |
2020-01-15 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 5,406 | 224,576 | 2.47 | 14.98 | 80,973 | 3,363,789 | |
2020-01-15 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 25,108 | 1,274,328 | 2.01 | 14.98 | 376,078 | 19,087,395 | |
2020-01-15 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 53,448 | 1,657,663 | 3.33 | 14.98 | 800,566 | 24,829,139 | |
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2019-12-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 32,606 | 536,608 | 6.47 | 4.05 | 132,054 | 2,173,262 | |
2019-12-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 201,096 | 3,078,989 | 6.99 | 4.05 | 814,439 | 12,469,905 | |
2019-12-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 281,318 | 3,929,792 | 7.71 | 4.05 | 1,139,338 | 15,915,658 | |
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 165,961 | 1,103,314 | 17.71 | 22.00 | 3,651,142 | 24,272,908 | |
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 207,234 | 1,147,676 | 22.04 | 22.00 | 4,559,148 | 25,248,872 | |
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Subscription Rights (right to buy) |
X - Other | -35,888 | 0 | -100.00 | ||||
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Subscription Rights (right to buy) |
X - Other | -190,899 | 0 | -100.00 | ||||
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Subscription Rights (right to buy) |
X - Other | -245,481 | 0 | -100.00 | ||||
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
X - Other | 35,888 | 159,537 | 29.02 | 22.00 | 789,536 | 3,509,814 | |
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
X - Other | 190,899 | 937,353 | 25.57 | 22.00 | 4,199,778 | 20,621,766 | |
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
X - Other | 245,481 | 940,442 | 35.32 | 22.00 | 5,400,582 | 20,689,724 | |
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 8,506 | 499,312 | 1.73 | 9.52 | 80,935 | 4,750,954 | |
2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 49,804 | 2,861,622 | 1.77 | 9.52 | 473,885 | 27,228,333 | |
2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 60,103 | 3,617,776 | 1.69 | 9.52 | 571,880 | 34,423,139 | |
2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 15,030 | 490,806 | 3.16 | 9.40 | 141,282 | 4,613,576 | |
2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 95,100 | 2,811,818 | 3.50 | 9.40 | 893,940 | 26,431,089 | |
2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 113,529 | 3,557,673 | 3.30 | 9.40 | 1,067,173 | 33,442,126 | |
2019-12-11 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2,397 | 504,002 | 0.48 | 4.02 | 9,630 | 2,024,828 | |
2019-12-11 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 18,729 | 2,877,893 | 0.66 | 4.02 | 75,244 | 11,561,935 | |
2019-12-11 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 113,874 | 3,648,474 | 3.22 | 4.02 | 457,489 | 14,657,744 | |
2019-11-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 81,857 | 501,605 | 19.50 | 3.40 | 278,322 | 1,705,507 | |
2019-11-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 462,056 | 2,859,164 | 19.28 | 3.40 | 1,571,037 | 9,721,444 | |
2019-11-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 576,097 | 3,534,600 | 19.47 | 3.40 | 1,958,787 | 12,017,993 | |
2019-11-22 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 14,151 | 672,682 | 2.15 | 3.91 | 55,353 | 2,631,263 | |
2019-11-22 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 79,285 | 3,830,893 | 2.11 | 3.91 | 310,131 | 14,984,921 | |
2019-11-22 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 98,518 | 4,739,356 | 2.12 | 3.91 | 385,363 | 18,538,465 | |
2019-11-18 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 11,105 | 658,531 | 1.72 | 3.37 | 37,424 | 2,219,249 | |
2019-11-18 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 45,888 | 3,751,608 | 1.24 | 3.37 | 154,643 | 12,642,919 | |
2019-11-18 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 71,495 | 4,640,838 | 1.56 | 3.37 | 240,938 | 15,639,624 | |
2019-11-07 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 70,921 | 419,748 | 20.33 | 4.00 | 283,684 | 1,678,992 | |
2019-11-07 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 400,470 | 2,397,108 | 20.06 | 4.00 | 1,601,880 | 9,588,432 | |
2019-11-07 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 496,721 | 2,958,503 | 20.18 | 4.00 | 1,986,884 | 11,834,012 | |
2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 57,868 | 647,426 | 9.82 | 2.70 | 156,244 | 1,748,050 | |
2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 331,048 | 3,705,720 | 9.81 | 2.70 | 893,830 | 10,005,444 | |
2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 408,592 | 4,569,343 | 9.82 | 2.70 | 1,103,198 | 12,337,226 | |
2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 116,552 | 589,558 | 24.64 | 2.60 | 303,035 | 1,532,851 | |
2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 610,052 | 3,374,672 | 22.07 | 2.60 | 1,586,135 | 8,774,147 | |
2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 872,373 | 4,160,751 | 26.53 | 2.60 | 2,268,170 | 10,817,953 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 504 | 348,827 | 0.14 | 3.85 | 1,940 | 1,342,844 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2,913 | 1,996,638 | 0.15 | 3.85 | 11,214 | 7,686,258 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 3,416 | 2,461,782 | 0.14 | 3.85 | 13,150 | 9,476,876 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,456 | 348,323 | 0.42 | 3.89 | 5,667 | 1,355,708 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 8,236 | 1,993,725 | 0.41 | 3.89 | 32,055 | 7,759,777 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 10,389 | 2,458,366 | 0.42 | 3.89 | 40,435 | 9,568,206 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 240 | 346,867 | 0.07 | 3.90 | 935 | 1,351,706 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,133 | 1,985,489 | 0.06 | 3.90 | 4,415 | 7,737,252 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,027 | 2,447,977 | 0.04 | 3.90 | 4,002 | 9,539,522 | |
2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2,155 | 346,627 | 0.63 | 3.75 | 8,075 | 1,298,915 | |
2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 12,899 | 1,984,356 | 0.65 | 3.75 | 48,336 | 7,435,977 | |
2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 15,728 | 2,446,950 | 0.65 | 3.75 | 58,938 | 9,169,456 | |
2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,629 | 344,472 | 0.48 | 3.74 | 6,100 | 1,289,944 | |
2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 57,723 | 1,971,457 | 3.02 | 3.74 | 216,155 | 7,382,515 | |
2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 76,036 | 2,431,222 | 3.23 | 3.74 | 284,732 | 9,104,197 | |
2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 3,200 | 2,355,186 | 0.14 | 3.75 | 11,986 | 8,821,349 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 4,689 | 342,843 | 1.39 | 3.68 | 17,270 | 1,262,691 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 24,716 | 1,913,734 | 1.31 | 3.68 | 91,029 | 7,048,282 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 31,007 | 2,351,986 | 1.34 | 3.68 | 114,199 | 8,662,364 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 24,425 | 338,154 | 7.79 | 3.75 | 91,594 | 1,268,078 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 14,242 | 313,729 | 4.76 | 3.75 | 53,382 | 1,175,919 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 138,609 | 1,889,018 | 7.92 | 3.75 | 519,784 | 7,083,818 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 80,821 | 1,750,409 | 4.84 | 3.75 | 302,933 | 6,560,883 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 168,640 | 2,320,979 | 7.84 | 3.75 | 632,400 | 8,703,671 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 98,333 | 2,152,339 | 4.79 | 3.75 | 368,572 | 8,067,397 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 991 | 299,487 | 0.33 | 3.74 | 3,704 | 1,119,333 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 7,314 | 1,669,588 | 0.44 | 3.74 | 27,336 | 6,240,085 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 7,695 | 2,054,006 | 0.38 | 3.74 | 28,760 | 7,676,847 | |
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-09-10 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -1,128 | 314,139 | -0.36 | 4.50 | -5,075 | 1,413,437 | |
2019-09-10 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -25,720 | 2,233,074 | -1.14 | 4.50 | -115,725 | 10,047,493 | |
2019-09-10 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -23,152 | 2,385,055 | -0.96 | 4.50 | -104,170 | 10,731,316 | |
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-09 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 124,956 | 528,891 | 30.93 | 3.18 | 397,610 | 1,682,931 | |
2019-09-09 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 689,834 | 2,955,440 | 30.45 | 3.18 | 2,195,052 | 9,404,210 | |
2019-09-09 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 853,956 | 3,639,935 | 30.65 | 3.18 | 2,717,288 | 11,582,273 | |
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-06-12 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -29,450 | 169,589 | -14.80 | 10.70 | -315,230 | 1,815,264 | |
2019-06-12 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -158,583 | 952,859 | -14.27 | 10.70 | -1,697,457 | 10,199,307 | |
2019-06-12 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -198,256 | 1,178,904 | -14.40 | 10.70 | -2,122,112 | 12,618,871 | |
2019-05-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 13,816 | 746,454 | 1.89 | 14.74 | 203,664 | 11,003,628 | |
2019-05-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,797 | 732,638 | 0.52 | 14.36 | 54,526 | 10,520,975 | |
2019-05-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10,300 | 728,841 | 1.43 | 14.57 | 150,037 | 10,616,808 | |
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock, $0.001 par value |
J - Other | 284 | 284 | |||||
2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock, $0.001 par value |
J - Other | 2,143 | 2,143 | |||||
2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock, $0.001 par value |
J - Other | 2,573 | 2,573 | |||||
2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
J - Other | -284,000 | 141,346 | -66.77 | ||||
2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
J - Other | -2,143,000 | 772,324 | -73.51 | ||||
2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
J - Other | -2,573,000 | 978,200 | -72.45 | ||||
2018-12-19 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
X - Other | 372 | 597 | 165.47 | 13,000.00 | 4,836,000 | 7,758,569 | |
2018-12-19 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
X - Other | 311 | 656 | 89.96 | 13,000.00 | 4,038,398 | 8,527,467 | |
2018-12-19 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 25,000 | 718,541 | 3.60 | 14.19 | 354,792 | 10,197,318 | |
2018-12-19 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
X - Other | 225 | 225 | 13,000.00 | 2,922,569 | 2,922,569 | ||
2018-12-19 |
|
4 | XOMA |
XOMA Corp
Subscription Rights |
X - Other | -225 | 0 | -100.00 | ||||
2018-12-19 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
X - Other | 345 | 345 | 13,000.00 | 4,489,069 | 4,489,069 | ||
2018-12-19 |
|
4 | XOMA |
XOMA Corp
Subscription Rights |
X - Other | -345 | 0 | -100.00 | ||||
2018-12-17 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 120,539 | 6,631,136 | 1.85 | 1.20 | 144,587 | 7,954,048 | |
2018-12-17 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 54,461 | 8,485,575 | 0.65 | 1.20 | 65,326 | 10,178,447 | |
2018-12-13 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 24,253 | 693,541 | 3.62 | 14.41 | 349,525 | 9,995,035 | |
2018-12-13 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 2,810 | 669,288 | 0.42 | 14.75 | 41,448 | 9,871,998 | |
2018-12-13 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9,400 | 666,478 | 1.43 | 14.50 | 136,270 | 9,661,798 | |
2018-12-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 18,081 | 657,078 | 2.83 | 14.54 | 262,972 | 9,556,608 | |
2018-12-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 32,015 | 638,997 | 5.27 | 14.77 | 472,778 | 9,436,324 | |
2018-12-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10,927 | 606,982 | 1.83 | 14.80 | 161,698 | 8,982,120 | |
2018-12-04 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4,171 | 596,055 | 0.70 | 14.99 | 62,515 | 8,933,672 | |
2018-12-04 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 806 | 591,884 | 0.14 | 14.90 | 12,009 | 8,819,072 | |
2018-12-04 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4,823 | 591,078 | 0.82 | 14.85 | 71,615 | 8,776,681 | |
2018-12-04 |
|
4 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
S - Sale | -89,948 | 370,391 | -19.54 | 1.83 | -164,929 | 679,149 | |
2018-12-04 |
|
4 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
S - Sale | -382,017 | 1,942,764 | -16.43 | 1.83 | -700,466 | 3,562,252 | |
2018-12-04 |
|
4 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
S - Sale | -430,035 | 2,502,758 | -14.66 | 1.83 | -788,512 | 4,589,057 | |
2018-11-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 100,000 | 6,510,597 | 1.56 | 1.30 | 130,000 | 8,463,776 | |
2018-11-29 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10,016 | 586,255 | 1.74 | 14.93 | 149,543 | 8,753,022 | |
2018-11-29 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 8,288 | 576,239 | 1.46 | 15.11 | 125,262 | 8,709,046 | |
2018-11-29 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 11,396 | 567,951 | 2.05 | 15.24 | 173,680 | 8,655,800 | |
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-21 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 25,000 | 556,555 | 4.70 | 15.00 | 374,892 | 8,345,932 | |
2018-11-21 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 37,482 | 531,555 | 7.59 | 13.68 | 512,701 | 7,270,928 | |
2018-11-21 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9,771 | 494,073 | 2.02 | 13.93 | 136,064 | 6,880,115 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 581 | 1,254,993 | 0.05 | 1.35 | 784 | 1,694,241 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 4,119 | 8,431,114 | 0.05 | 1.35 | 5,561 | 11,382,004 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 5,573 | 1,254,412 | 0.45 | 1.35 | 7,524 | 1,693,456 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 38,001 | 6,410,597 | 0.60 | 1.35 | 51,301 | 8,654,306 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 50,044 | 8,426,995 | 0.60 | 1.35 | 67,559 | 11,376,443 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 81,648 | 1,248,839 | 7.00 | 1.37 | 111,841 | 1,710,660 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 556,709 | 6,372,596 | 9.57 | 1.37 | 762,580 | 8,729,182 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 733,151 | 8,376,951 | 9.59 | 1.37 | 1,004,270 | 11,474,747 | |
2018-11-19 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10,849 | 484,302 | 2.29 | 13.82 | 149,986 | 6,695,427 | |
2018-11-19 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 21,141 | 473,453 | 4.67 | 13.31 | 281,361 | 6,301,091 | |
2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 39,074 | 5,815,887 | 0.68 | 1.35 | 52,750 | 7,851,447 | |
2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 52,400 | 7,643,800 | 0.69 | 1.35 | 70,740 | 10,319,130 | |
2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 92,960 | 5,776,813 | 1.64 | 1.34 | 124,566 | 7,740,929 | |
2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 117,290 | 7,591,400 | 1.57 | 1.34 | 157,169 | 10,172,476 | |
2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 562,754 | 5,683,853 | 10.99 | 1.35 | 759,718 | 7,673,202 | |
2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 41,454 | 7,474,110 | 0.56 | 1.35 | 55,963 | 10,090,048 | |
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 36,825 | 1,167,191 | 3.26 | 1.65 | 60,761 | 1,925,865 | |
2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 158,151 | 5,121,099 | 3.19 | 1.65 | 260,949 | 8,449,813 | |
2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 230,555 | 7,432,656 | 3.20 | 1.65 | 380,416 | 12,263,882 | |
2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 179,893 | 1,130,366 | 18.93 | 1.65 | 296,823 | 1,865,104 | |
2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,419,907 | 4,962,948 | 40.08 | 1.65 | 2,342,847 | 8,188,864 | |
2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,916,760 | 7,202,101 | 36.27 | 1.65 | 3,162,654 | 11,883,467 | |
2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Warrants |
J - Other | 188,746 | 188,746 | |||||
2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Warrants |
J - Other | 705,863 | 705,863 | |||||
2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Warrants |
J - Other | 1,105,391 | 1,105,391 | |||||
2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
J - Other | -188,746 | 85,038 | -68.94 | ||||
2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
J - Other | -705,863 | 318,021 | -68.94 | ||||
2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
J - Other | -1,105,391 | 498,025 | -68.94 | ||||
2018-06-01 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -175,813 | 771,305 | -18.56 | 5.00 | -879,083 | 3,856,602 | |
2018-06-01 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -312,266 | 3,186,044 | -8.93 | 5.00 | -1,561,361 | 15,930,539 | |
2018-06-01 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -547,860 | 4,682,669 | -10.47 | 5.00 | -2,739,355 | 23,413,813 | |
2018-04-20 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -217,256 | 947,118 | -18.66 | 3.10 | -673,494 | 2,936,066 | |
2018-04-20 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -808,449 | 3,498,310 | -18.77 | 3.10 | -2,506,192 | 10,844,761 | |
2018-04-20 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -1,204,668 | 5,230,529 | -18.72 | 3.10 | -3,734,471 | 16,214,640 | |
2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 97,453 | 950,473 | 11.42 | 2.00 | 194,906 | 1,900,946 | |
2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 365,682 | 3,543,041 | 11.51 | 2.00 | 731,364 | 7,086,082 | |
2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 546,865 | 5,285,341 | 11.54 | 2.00 | 1,093,730 | 10,570,682 | |
2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 62,437 | 853,020 | 7.90 | 1.90 | 118,630 | 1,620,738 | |
2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 208,872 | 3,177,359 | 7.04 | 1.90 | 396,857 | 6,036,982 | |
2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 228,691 | 4,738,476 | 5.07 | 1.90 | 434,513 | 9,003,104 | |
2018-04-06 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -214,336 | 1,164,374 | -15.55 | 2.90 | -621,574 | 3,376,685 | |
2018-04-06 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -817,611 | 4,306,759 | -15.96 | 2.90 | -2,371,072 | 12,489,601 | |
2018-04-06 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -1,269,634 | 6,435,197 | -16.48 | 2.90 | -3,681,939 | 18,662,071 | |
2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Series 1 Preferred Shares |
J - Other | 238,000 | 238,000 | |||||
2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Series 1 Preferred Shares |
J - Other | 861,000 | 861,000 | |||||
2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Series 1 Preferred Shares |
J - Other | 1,338,000 | 1,338,000 | |||||
2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Shares, no par value per share |
J - Other | -238,000 | 59,464 | -80.01 | ||||
2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Shares, no par value per share |
J - Other | -861,000 | 216,694 | -79.89 | ||||
2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Shares, no par value per share |
J - Other | -1,338,000 | 336,468 | -79.91 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series O Preferred Stock |
A - Award | 2,280 | 2,280 | |||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series O Preferred Stock |
A - Award | 1,024 | 1,024 | |||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series O Preferred Stock |
A - Award | 3,640 | 3,640 | |||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series O Preferred Stock |
A - Award | 5,631 | 5,631 | |||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N Preferred Stock |
D - Sale to Issuer | -49 | 0 | -100.00 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N Preferred Stock |
D - Sale to Issuer | -48 | 0 | -100.00 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N Preferred Stock |
D - Sale to Issuer | -197 | 0 | -100.00 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N Preferred Stock |
D - Sale to Issuer | -281 | 0 | -100.00 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 699,225 | 1,295,582 | 117.25 | 3.00 | 2,097,675 | 3,886,746 | |
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 483,708 | 483,708 | 3.00 | 1,451,124 | 1,451,124 | ||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 2,109,280 | 2,109,280 | 3.00 | 6,327,840 | 6,327,840 | ||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 3,041,120 | 3,041,120 | 3.00 | 9,123,360 | 9,123,360 | ||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
D - Sale to Issuer | -1,487,294 | 596,357 | -71.38 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
D - Sale to Issuer | -651,074 | 0 | -100.00 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
D - Sale to Issuer | -2,295,083 | 0 | -100.00 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
D - Sale to Issuer | -3,566,549 | 0 | -100.00 | ||||
2017-12-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -169,292 | 122,496 | -58.02 | 26.65 | -4,511,632 | 3,264,518 | |
2017-12-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -445,615 | 632,642 | -41.33 | 26.65 | -11,875,640 | 16,859,909 | |
2017-12-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -667,949 | 951,300 | -41.25 | 26.65 | -17,800,841 | 25,352,145 | |
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-10-23 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 34,632 | 291,788 | 13.47 | 15.84 | 548,484 | 4,621,192 | |
2017-10-23 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 135,206 | 1,078,257 | 14.34 | 15.84 | 2,141,325 | 17,076,895 | |
2017-10-23 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 162,078 | 1,619,249 | 11.12 | 15.84 | 2,566,910 | 25,644,856 | |
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 63,042 | 790,583 | 8.67 | 1.28 | 80,946 | 1,015,109 | |
2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 235,326 | 2,968,487 | 8.61 | 1.28 | 302,159 | 3,811,537 | |
2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 355,081 | 4,509,785 | 8.55 | 1.28 | 455,924 | 5,790,564 | |
2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 28,918 | 727,541 | 4.14 | 1.24 | 35,714 | 898,513 | |
2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 394,078 | 2,733,161 | 16.85 | 1.24 | 486,686 | 3,375,454 | |
2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 523,601 | 4,154,704 | 14.42 | 1.24 | 646,647 | 5,131,059 | |
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-08-16 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 7,429 | 1,077,694 | 0.69 | 2.41 | 17,920 | 2,599,613 | |
2017-08-16 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 11,429 | 1,674,468 | 0.69 | 2.41 | 27,569 | 4,039,152 | |
2017-08-16 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 13,337 | 1,070,265 | 1.26 | 2.70 | 36,058 | 2,893,568 | |
2017-08-16 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 28,007 | 1,663,039 | 1.71 | 2.70 | 75,720 | 4,496,192 | |
2017-07-18 |
|
4 | CAPS |
Capstone Therapeutics Corp.
Common Stock, $0.0005 par value |
S - Sale | -105,713 | 890,487 | -10.61 | 0.06 | -6,343 | 53,429 | |
2017-07-18 |
|
4 | CAPS |
Capstone Therapeutics Corp.
Common Stock, $0.0005 par value |
S - Sale | -242,236 | 1,377,652 | -14.95 | 0.06 | -14,534 | 82,659 | |
2017-07-18 |
|
4 | CAPS |
Capstone Therapeutics Corp.
Common Stock, $0.0005 par value |
S - Sale | -3,993,637 | 0 | -100.00 | 0.06 | -239,618 | ||
2017-06-30 |
|
4/A | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 8,496 | 297,464 | 2.94 | 3.04 | 25,795 | 903,130 | |
2017-06-30 |
|
4/A | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 30,170 | 1,056,928 | 2.94 | 3.04 | 91,599 | 3,208,939 | |
2017-06-30 |
|
4/A | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 46,795 | 1,635,032 | 2.95 | 3.04 | 142,074 | 4,964,121 | |
2017-06-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 8,496 | 297,464 | 2.94 | 4.00 | 33,984 | 1,189,856 | |
2017-06-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 30,170 | 1,056,928 | 2.94 | 4.00 | 120,680 | 4,227,712 | |
2017-06-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 46,795 | 1,635,032 | 2.95 | 4.00 | 187,180 | 6,540,128 | |
2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 854 | 288,968 | 0.30 | 4.00 | 3,416 | 1,155,872 | |
2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 2,884 | 1,026,758 | 0.28 | 4.00 | 11,536 | 4,107,032 | |
2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 4,525 | 1,588,237 | 0.29 | 4.00 | 18,100 | 6,352,948 | |
2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1,362 | 288,114 | 0.47 | 4.00 | 5,448 | 1,152,456 | |
2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 4,406 | 1,023,874 | 0.43 | 4.00 | 17,624 | 4,095,496 | |
2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 6,380 | 1,583,712 | 0.40 | 4.00 | 25,520 | 6,334,848 | |
2017-06-22 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1,715 | 201,811 | 0.86 | 2.25 | 3,859 | 454,075 | |
2017-06-22 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,359 | 717,089 | 0.89 | 2.25 | 14,308 | 1,613,450 | |
2017-06-22 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 9,732 | 1,109,258 | 0.89 | 2.25 | 21,897 | 2,495,830 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 357 | 286,752 | 0.12 | 3.85 | 1,374 | 1,103,995 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1,271 | 1,019,468 | 0.12 | 3.85 | 4,893 | 3,924,952 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1,967 | 1,577,332 | 0.12 | 3.85 | 7,573 | 6,072,728 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1,064 | 286,395 | 0.37 | 3.85 | 4,096 | 1,102,621 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 3,873 | 1,018,197 | 0.38 | 3.85 | 14,911 | 3,920,058 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 6,097 | 1,575,365 | 0.39 | 3.85 | 23,473 | 6,065,155 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1,160 | 285,331 | 0.41 | 3.84 | 4,451 | 1,094,815 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 3,845 | 1,014,324 | 0.38 | 3.84 | 14,753 | 3,891,961 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 6,774 | 1,569,268 | 0.43 | 3.84 | 25,992 | 6,021,281 | |
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
C - Conversion | -536 | 49 | -91.62 | ||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
C - Conversion | -513 | 48 | -91.44 | ||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
C - Conversion | -2,115 | 197 | -91.48 | ||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
C - Conversion | -3,011 | 281 | -91.46 | ||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
P - Purchase | 585 | 585 | |||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
P - Purchase | 561 | 561 | |||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
P - Purchase | 2,312 | 2,312 | |||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
P - Purchase | 3,292 | 3,292 | |||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
C - Conversion | 357,333 | 2,083,651 | 20.70 | ||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
C - Conversion | 342,000 | 651,074 | 110.65 | ||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
C - Conversion | 1,410,000 | 2,295,083 | 159.31 | ||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
C - Conversion | 2,007,333 | 3,566,549 | 128.74 | ||||
2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 20,594 | 284,171 | 7.81 | 3.85 | 79,312 | 1,094,399 | |
2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 73,749 | 1,010,479 | 7.87 | 3.85 | 284,022 | 3,891,557 | |
2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 113,446 | 1,562,494 | 7.83 | 3.85 | 436,903 | 6,017,477 | |
2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 913 | 263,577 | 0.35 | 3.75 | 3,424 | 988,414 | |
2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 53,260 | 936,730 | 6.03 | 3.75 | 199,725 | 3,512,738 | |
2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 96,736 | 1,449,048 | 7.15 | 3.75 | 362,760 | 5,433,930 | |
2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 3,673 | 200,096 | 1.87 | 2.28 | 8,379 | 456,479 | |
2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 13,046 | 710,730 | 1.87 | 2.28 | 29,762 | 1,621,388 | |
2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 20,181 | 1,099,526 | 1.87 | 2.28 | 46,039 | 2,508,349 | |
2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 3,920 | 196,423 | 2.04 | 2.29 | 8,979 | 449,927 | |
2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 12,624 | 697,684 | 1.84 | 2.29 | 28,917 | 1,598,115 | |
2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 19,206 | 1,079,345 | 1.81 | 2.29 | 43,993 | 2,472,348 | |
2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 2,727 | 192,503 | 1.44 | 2.25 | 6,128 | 432,554 | |
2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 10,023 | 685,060 | 1.48 | 2.25 | 22,522 | 1,539,330 | |
2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 15,350 | 1,060,139 | 1.47 | 2.25 | 34,491 | 2,382,132 | |
2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1,805 | 189,776 | 0.96 | 2.30 | 4,144 | 435,669 | |
2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,903 | 675,037 | 1.03 | 2.30 | 15,847 | 1,549,682 | |
2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 10,192 | 1,044,789 | 0.99 | 2.30 | 23,398 | 2,398,522 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1,124 | 187,971 | 0.60 | 2.30 | 2,585 | 432,333 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 4,223 | 668,134 | 0.64 | 2.30 | 9,713 | 1,536,708 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,253 | 1,034,597 | 0.61 | 2.30 | 14,382 | 2,379,573 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 2,909 | 186,847 | 1.58 | 2.30 | 6,690 | 429,711 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 10,541 | 663,911 | 1.61 | 2.30 | 24,242 | 1,526,863 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 16,436 | 1,028,344 | 1.62 | 2.30 | 37,800 | 2,364,986 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 5,510 | 183,938 | 3.09 | 2.30 | 12,666 | 422,818 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,897 | 653,370 | 1.07 | 2.30 | 15,854 | 1,501,902 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 24,965 | 1,011,908 | 2.53 | 2.30 | 57,387 | 2,326,073 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 675 | 178,428 | 0.38 | 2.34 | 1,581 | 418,039 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 2,565 | 646,473 | 0.40 | 2.34 | 6,010 | 1,514,622 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 3,794 | 986,943 | 0.39 | 2.34 | 8,889 | 2,312,309 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,217 | 177,753 | 3.62 | 2.35 | 14,583 | 416,955 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 22,092 | 643,908 | 3.55 | 2.35 | 51,821 | 1,510,415 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 33,691 | 983,149 | 3.55 | 2.35 | 79,029 | 2,306,173 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 3,929 | 171,536 | 2.34 | 2.29 | 8,989 | 392,457 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 14,274 | 621,816 | 2.35 | 2.29 | 32,657 | 1,422,653 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 21,797 | 949,458 | 2.35 | 2.29 | 49,869 | 2,172,265 | |
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-01-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 3,234 | 2,339,083 | 0.14 | 1.34 | 4,333 | 3,133,669 | |
2017-01-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,145 | 3,631,103 | 0.03 | 1.34 | 1,534 | 4,864,589 | |
2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,205 | 2,335,849 | 0.05 | 1.34 | 1,614 | 3,129,103 | |
2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2,348 | 3,629,958 | 0.06 | 1.34 | 3,145 | 4,862,692 | |
2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 77,076 | 698,623 | 12.40 | 1.34 | 102,943 | 933,081 | |
2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 260,046 | 2,334,644 | 12.53 | 1.34 | 347,317 | 3,118,151 | |
2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 401,726 | 3,627,610 | 12.45 | 1.34 | 536,545 | 4,845,036 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2,244 | 621,547 | 0.36 | 1.35 | 3,040 | 842,134 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 8,111 | 2,074,598 | 0.39 | 1.35 | 10,990 | 2,810,873 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 11,646 | 3,225,884 | 0.36 | 1.35 | 15,779 | 4,370,750 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 21,021 | 619,303 | 3.51 | 1.36 | 28,555 | 841,261 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 69,041 | 2,066,487 | 3.46 | 1.36 | 93,785 | 2,807,116 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 108,202 | 3,214,238 | 3.48 | 1.36 | 146,982 | 4,366,221 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 47,812 | 598,282 | 8.69 | 1.28 | 61,199 | 765,801 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 150,451 | 1,997,446 | 8.15 | 1.28 | 192,577 | 2,556,731 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 236,393 | 3,106,036 | 8.24 | 1.28 | 302,583 | 3,975,726 | |
2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2,916 | 550,470 | 0.53 | 1.19 | 3,470 | 655,114 | |
2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 18,586 | 1,846,995 | 1.02 | 1.19 | 22,119 | 2,198,109 | |
2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 30,998 | 2,869,643 | 1.09 | 1.19 | 36,891 | 3,415,162 | |
2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 15,161 | 547,554 | 2.85 | 1.18 | 17,958 | 648,578 | |
2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 52,457 | 1,828,409 | 2.95 | 1.18 | 62,135 | 2,165,750 | |
2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 81,276 | 2,838,645 | 2.95 | 1.18 | 96,271 | 3,362,375 | |
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-06-27 |
|
4 | ONTY |
Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock |
A - Award | 6,197 | 6,197 | 800.00 | 4,957,600 | 4,957,600 | ||
2016-06-27 |
|
4 | ONTY |
Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock |
A - Award | 1,029 | 1,029 | 800.00 | 823,200 | 823,200 | ||
2016-06-27 |
|
4 | ONTY |
Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock |
A - Award | 4,519 | 4,519 | 800.00 | 3,615,200 | 3,615,200 | ||
2016-06-27 |
|
4 | ONTY |
Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock |
A - Award | 5,505 | 5,505 | 800.00 | 4,404,000 | 4,404,000 | ||
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 58,613 | 17,263,200 | 0.34 | 1.22 | 71,338 | 21,011,041 | |
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 32,571 | 3,090,744 | 1.07 | 1.22 | 39,642 | 3,761,745 | |
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 90,049 | 8,850,836 | 1.03 | 1.22 | 109,599 | 10,772,352 | |
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 186,314 | 15,592,160 | 1.21 | 1.22 | 226,763 | 18,977,218 | |
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 8,091 | 17,204,587 | 0.05 | 1.22 | 9,848 | 20,939,703 | |
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 29,655 | 3,058,173 | 0.98 | 1.22 | 36,093 | 3,722,102 | |
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 87,747 | 8,760,787 | 1.01 | 1.22 | 106,797 | 10,662,754 | |
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 508,287 | 15,405,846 | 3.41 | 1.22 | 618,636 | 18,750,455 | |
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 | ||||||||
2015-11-05 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
J - Other | -2,384,577 | 0 | -100.00 | ||||
2015-11-05 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
S - Sale | -287,000 | 2,384,577 | -10.74 | 7.00 | -2,009,057 | 16,692,516 | |
2015-11-05 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
S - Sale | -73,000 | 2,671,577 | -2.66 | 6.98 | -509,343 | 18,640,394 | |
2015-11-02 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
S - Sale | -50,000 | 2,744,577 | -1.79 | 6.97 | -348,515 | 19,130,525 | |
2015-06-11 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
S - Sale | -31,000 | 2,794,577 | -1.10 | 9.01 | -279,229 | 25,171,873 | |
2015-06-11 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
S - Sale | -924,700 | 2,825,577 | -24.66 | 9.00 | -8,322,392 | 25,430,476 | |
2015-02-09 |
|
4 | ONTY |
Oncothyreon Inc.
Preferred Stock, $0.0001 per share |
J - Other | 1,400 | 1,400 | |||||
2015-02-09 |
|
4 | ONTY |
Oncothyreon Inc.
Preferred Stock, $0.0001 per share |
J - Other | 2,600 | 2,600 | |||||
2015-02-09 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
J - Other | -1,400,000 | 1,898,293 | -42.45 | ||||
2015-02-09 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
J - Other | -2,600,000 | 3,762,683 | -40.86 | ||||
2014-12-17 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
P - Purchase | 55,197 | 3,298,293 | 1.70 | 1.73 | 95,662 | 5,716,272 | |
2014-12-17 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
P - Purchase | 98,298 | 6,362,683 | 1.57 | 1.73 | 170,360 | 11,027,166 | |
2014-12-17 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
P - Purchase | 79,434 | 3,243,096 | 2.51 | 1.88 | 149,249 | 6,093,453 | |
2014-12-17 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
P - Purchase | 145,515 | 6,264,385 | 2.38 | 1.88 | 273,408 | 11,770,153 | |
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
15,401,402 | ||||||||
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
12,446,194 | ||||||||
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
15,401,402 | ||||||||
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
12,446,194 | ||||||||
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
15,401,402 | ||||||||
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
12,446,194 | ||||||||
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
15,401,402 | ||||||||
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
12,446,194 | ||||||||
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
15,401,402 | ||||||||
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
12,446,194 | ||||||||
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
15,401,402 | ||||||||
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
12,446,194 | ||||||||
2014-07-16 |
|
4 | ONTY |
Oncothyreon Inc.
Warrants |
J - Other | -242,814 | 1,223,484 | -16.56 | 1.59 | -386,074 | 1,945,340 | |
2014-07-16 |
|
4 | ONTY |
Oncothyreon Inc.
Warrants |
J - Other | -407,136 | 2,288,698 | -15.10 | 1.59 | -647,346 | 3,639,030 | |
2014-07-16 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
J - Other | -258,230 | 2,412,290 | -9.67 | 3.24 | -836,665 | 7,815,820 | |
2014-07-16 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
J - Other | -296,008 | 4,512,523 | -6.16 | 3.24 | -959,066 | 14,620,575 | |
2014-07-10 |
|
4 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
J - Other | -494,092 | 7,058,997 | -6.54 | 4.56 | -2,253,060 | 32,189,026 | |
2014-07-03 |
|
4 | CAPS |
Capstone Therapeutics Corp.
Common Stock, $0.0005 par value |
J - Other | -616,563 | 3,993,637 | -13.37 | 0.30 | -184,969 | 1,198,091 | |
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
16,369,219 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
14,974,663 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
20,518,746 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
16,369,219 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
14,974,663 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
20,518,746 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
16,369,219 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
14,974,663 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
20,518,746 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
16,369,219 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
14,974,663 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
20,518,746 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
16,369,219 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
14,974,663 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
20,518,746 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
16,369,219 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
14,974,663 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
20,518,746 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
16,369,219 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
14,974,663 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
20,518,746 | ||||||||
2014-03-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -10,203 | 130,175 | -7.27 | 69.95 | -713,734 | 9,106,171 | |
2014-03-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -18,019 | 230,125 | -7.26 | 69.95 | -1,260,489 | 16,098,003 | |
2014-03-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -18,306 | 140,378 | -11.54 | 70.17 | -1,284,483 | 9,849,945 | |
2014-03-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -31,698 | 248,144 | -11.33 | 70.17 | -2,224,163 | 17,411,594 | |
2014-03-25 |
|
4 | RGDO |
Regado Biosciences Inc
Preferred Stock, $0.001 per share |
J - Other | 2,632 | 2,632 | |||||
2014-03-25 |
|
4 | RGDO |
Regado Biosciences Inc
Preferred Stock, $0.001 per share |
J - Other | 4,577 | 4,577 | |||||
2014-03-25 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock, $0.001 par value |
J - Other | -526,436 | 1,121,221 | -31.95 | ||||
2014-03-25 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock, $0.001 par value |
J - Other | -915,345 | 1,979,670 | -31.62 | ||||
2014-03-03 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -200,827 | 2,494,521 | -7.45 | 1.09 | -218,901 | 2,719,028 | |
2014-03-03 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -33,610 | 438,127 | -7.12 | 1.09 | -36,635 | 477,558 | |
2014-03-03 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -59,388 | 772,480 | -7.14 | 1.09 | -64,733 | 842,003 | |
2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -33,236 | 2,695,348 | -1.22 | 1.11 | -36,869 | 2,989,950 | |
2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -4,416 | 471,737 | -0.93 | 1.11 | -4,899 | 523,298 | |
2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -7,745 | 831,868 | -0.92 | 1.11 | -8,592 | 922,791 | |
2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -151,535 | 2,728,584 | -5.26 | 1.12 | -169,659 | 3,054,923 | |
2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -25,060 | 476,153 | -5.00 | 1.12 | -28,057 | 533,101 | |
2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -44,147 | 839,613 | -5.00 | 1.12 | -49,427 | 940,031 | |
2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -191,804 | 2,880,119 | -6.24 | 1.16 | -222,838 | 3,346,122 | |
2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -29,710 | 501,213 | -5.60 | 1.16 | -34,517 | 582,309 | |
2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -52,528 | 883,760 | -5.61 | 1.16 | -61,027 | 1,026,752 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -5,359 | 79,390 | -6.32 | 73.05 | -391,464 | 5,799,273 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -112,369 | 1,685,344 | -6.25 | 73.05 | -8,208,319 | 123,110,840 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -10,557 | 158,684 | -6.24 | 73.05 | -771,167 | 11,591,533 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -18,615 | 279,842 | -6.24 | 73.05 | -1,359,787 | 20,441,870 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -2,771 | 84,749 | -3.17 | 73.03 | -202,375 | 6,189,499 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -57,370 | 1,797,713 | -3.09 | 73.03 | -4,189,920 | 131,292,913 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -5,395 | 169,241 | -3.09 | 73.03 | -394,015 | 12,360,229 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -9,464 | 298,457 | -3.07 | 73.03 | -691,187 | 21,797,300 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -14,003 | 87,520 | -13.79 | 74.66 | -1,045,409 | 6,533,902 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -153,751 | 1,855,083 | -7.65 | 74.66 | -11,478,450 | 138,493,262 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -16,331 | 174,636 | -8.55 | 74.66 | -1,219,209 | 13,037,643 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -16,915 | 307,921 | -5.21 | 74.66 | -1,262,808 | 22,988,181 | |
2014-02-19 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -19,077 | 3,071,923 | -0.62 | 1.11 | -21,216 | 3,416,286 | |
2014-02-19 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -10,470 | 530,923 | -1.93 | 1.11 | -11,644 | 590,439 | |
2014-02-19 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -14,059 | 936,288 | -1.48 | 1.11 | -15,635 | 1,041,246 | |
2014-02-19 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -110,885 | 541,393 | -17.00 | 1.18 | -130,623 | 637,761 | |
2014-02-19 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -122,443 | 950,347 | -11.41 | 1.18 | -144,238 | 1,119,509 | |
2014-02-19 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -15,622 | 652,278 | -2.34 | 1.16 | -18,139 | 757,360 | |
2014-02-19 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -13,410 | 1,072,790 | -1.23 | 1.16 | -15,570 | 1,245,616 | |
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
5,080,487 | ||||||||
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
4,222,129 | ||||||||
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
5,080,487 | ||||||||
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
4,222,129 | ||||||||
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
5,080,487 | ||||||||
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
4,222,129 | ||||||||
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
5,080,487 | ||||||||
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
4,222,129 | ||||||||
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
5,080,487 | ||||||||
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
4,222,129 | ||||||||
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
5,080,487 | ||||||||
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
4,222,129 | ||||||||
2013-12-05 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 41,451 | 1,251,914 | 3.42 | 5.03 | 208,358 | 6,292,871 | |
2013-12-05 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 82,849 | 2,162,381 | 3.98 | 5.03 | 416,449 | 10,869,424 | |
2013-12-05 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 16,175 | 1,210,463 | 1.35 | 4.98 | 80,590 | 6,031,011 | |
2013-12-05 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 49,325 | 2,079,532 | 2.43 | 4.98 | 245,757 | 10,361,060 | |
2013-11-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -154,578 | 2,008,834 | -7.15 | 57.07 | -8,822,493 | 114,653,598 | |
2013-11-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -27,058 | 101,523 | -21.04 | 57.07 | -1,544,327 | 5,794,395 | |
2013-11-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -50,934 | 190,967 | -21.06 | 57.07 | -2,907,043 | 10,899,384 | |
2013-11-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -86,435 | 324,836 | -21.02 | 57.07 | -4,933,252 | 18,539,917 | |
2013-11-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -34,917 | 128,581 | -21.36 | 57.57 | -2,010,172 | 7,402,408 | |
2013-11-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -54,444 | 241,901 | -18.37 | 57.57 | -3,134,341 | 13,926,241 | |
2013-11-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -119,139 | 411,271 | -22.46 | 57.57 | -6,858,832 | 23,676,871 | |
2013-11-20 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
S - Sale | -153,056 | 646,559 | -19.14 | 2.64 | -404,343 | 1,708,080 | |
2013-11-20 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
S - Sale | -331,566 | 1,123,848 | -22.78 | 2.64 | -875,931 | 2,968,982 | |
2013-11-06 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 8,371 | 1,194,288 | 0.71 | 4.69 | 39,235 | 5,597,628 | |
2013-11-06 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 11,985 | 2,030,207 | 0.59 | 4.69 | 56,174 | 9,515,580 | |
2013-11-06 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 74,684 | 1,185,917 | 6.72 | 4.97 | 370,978 | 5,890,806 | |
2013-11-06 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 35,526 | 2,018,222 | 1.79 | 4.97 | 176,468 | 10,025,114 | |
2013-11-06 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 5,500 | 1,111,233 | 0.50 | 4.90 | 26,944 | 5,443,819 | |
2013-11-05 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 79,360 | 2,670,520 | 3.06 | 1.78 | 141,261 | 4,753,526 | |
2013-11-05 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 49,640 | 4,808,531 | 1.04 | 1.78 | 88,359 | 8,559,185 | |
2013-11-01 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 25,154 | 1,105,733 | 2.33 | 4.92 | 123,775 | 5,440,980 | |
2013-11-01 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 45,406 | 1,982,696 | 2.34 | 4.92 | 223,429 | 9,756,252 | |
2013-11-01 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 44,584 | 1,080,579 | 4.30 | 4.97 | 221,373 | 5,365,399 | |
2013-11-01 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 79,998 | 1,937,290 | 4.31 | 4.97 | 397,214 | 9,619,226 | |
2013-11-01 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 50,339 | 1,035,995 | 5.11 | 5.04 | 253,693 | 5,221,104 | |
2013-11-01 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 90,744 | 1,857,292 | 5.14 | 5.04 | 457,323 | 9,360,194 | |
2013-10-10 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 29,564 | 985,656 | 3.09 | 5.26 | 155,445 | 5,182,481 | |
2013-10-10 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 53,271 | 1,766,548 | 3.11 | 5.26 | 280,094 | 9,288,333 | |
2013-10-10 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 401,675 | 956,092 | 72.45 | 5.35 | 2,148,961 | 5,115,092 | |
2013-10-10 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 30,406 | 554,417 | 5.80 | 5.31 | 161,310 | 2,941,293 | |
2013-10-10 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 726,626 | 1,713,277 | 73.65 | 5.35 | 3,887,449 | 9,166,032 | |
2013-10-10 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 47,812 | 986,651 | 5.09 | 5.31 | 253,652 | 5,234,381 | |
2013-10-07 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 38,599 | 524,011 | 7.95 | 5.49 | 212,071 | 2,879,021 | |
2013-10-07 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 70,826 | 938,839 | 8.16 | 5.49 | 389,132 | 5,158,169 | |
2013-09-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -147,806 | 296,345 | -33.28 | 44.50 | -6,577,367 | 13,187,352 | |
2013-09-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -211,217 | 530,410 | -28.48 | 44.50 | -9,399,156 | 23,603,245 | |
2013-09-13 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 3,370 | 485,412 | 0.70 | 6.09 | 20,520 | 2,955,722 | |
2013-09-13 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 6,307 | 868,013 | 0.73 | 6.09 | 38,404 | 5,285,418 | |
2013-09-13 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 105,892 | 482,042 | 28.15 | 5.94 | 629,136 | 2,863,956 | |
2013-09-13 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 210,066 | 861,706 | 32.24 | 5.94 | 1,248,065 | 5,119,654 | |
2013-08-12 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 177,940 | 2,591,160 | 7.37 | 1.65 | 293,512 | 4,274,118 | |
2013-08-12 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 80,421 | 4,758,891 | 1.72 | 1.65 | 132,654 | 7,849,791 | |
2013-08-02 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 35,703 | 2,413,220 | 1.50 | 1.78 | 63,651 | 4,302,289 | |
2013-08-02 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 122,641 | 4,678,470 | 2.69 | 1.78 | 218,644 | 8,340,776 | |
2013-08-02 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 179,743 | 4,555,829 | 4.11 | 1.71 | 307,307 | 7,789,101 | |
2013-06-11 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
P - Purchase | 8,102 | 799,615 | 1.02 | 3.47 | 28,095 | 2,772,825 | |
2013-06-11 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
P - Purchase | 24,598 | 1,455,414 | 1.72 | 3.47 | 85,298 | 5,046,939 | |
2013-06-07 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 41,526 | 2,377,517 | 1.78 | 1.83 | 76,009 | 4,351,807 | |
2013-06-07 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 74,726 | 4,376,086 | 1.74 | 1.83 | 136,778 | 8,009,988 | |
2013-06-07 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 27,384 | 2,335,991 | 1.19 | 1.78 | 48,768 | 4,160,166 | |
2013-06-07 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 55,531 | 4,301,360 | 1.31 | 1.78 | 98,895 | 7,660,292 | |
2013-06-07 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 5,000 | 2,308,607 | 0.22 | 1.75 | 8,750 | 4,040,062 | |
2013-06-07 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 10,300 | 4,245,829 | 0.24 | 1.75 | 18,025 | 7,430,201 | |
2013-06-07 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
4,235,529 | ||||||||
2013-06-07 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
2,303,607 | ||||||||
2013-06-07 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
1,298,842 | ||||||||
2013-05-15 | 3 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock, $0.001 par value |
1,430,816 | ||||||||
2013-05-15 | 3 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock, $0.001 par value |
791,513 | ||||||||
2013-05-15 | 3 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock, $0.001 par value |
6,962,123 | ||||||||
2013-05-15 | 3 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock, $0.001 par value |
513,545 | ||||||||
2013-01-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 39,600 | 2,163,412 | 1.86 | 19.78 | 783,181 | 42,786,448 | |
2012-12-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 5,386 | 2,123,812 | 0.25 | 18.63 | 100,365 | 39,575,962 | |
2012-12-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 50,100 | 2,118,426 | 2.42 | 17.94 | 898,959 | 38,011,553 | |
2012-11-20 |
|
4/A | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 217,000 | 1,713,907 | 14.50 | 4.00 | 867,935 | 6,855,114 | |
2012-11-20 |
|
4/A | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 378,000 | 2,977,919 | 14.54 | 4.00 | 1,511,887 | 11,910,783 | |
2012-11-19 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 26,800 | 1,523,707 | 1.79 | 5.11 | 136,902 | 7,783,552 | |
2012-11-19 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 46,700 | 2,646,619 | 1.80 | 5.11 | 238,558 | 13,519,724 | |
2012-11-19 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 444,649 | 1,496,907 | 42.26 | 4.00 | 1,778,596 | 5,987,628 | |
2012-11-19 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 772,063 | 2,599,919 | 42.24 | 4.00 | 3,088,252 | 10,399,676 | |
2012-11-19 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
790,501 | ||||||||
2012-11-19 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
456,746 | ||||||||
2012-11-19 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
9,894,589 | ||||||||
2012-11-19 |
|
4/A | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 40,000 | 3,750,277 | 1.08 | 12.00 | 479,828 | 44,987,198 | |
2012-11-19 |
|
4/A | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 4,076 | 741,627 | 0.55 | 14.99 | 61,096 | 11,116,395 | |
2012-11-19 |
|
4/A | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 12,515 | 737,551 | 1.73 | 15.26 | 190,926 | 11,251,931 | |
2012-11-09 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 17,400 | 1,052,258 | 1.68 | 4.01 | 69,718 | 4,216,187 | |
2012-11-09 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 31,929 | 1,827,856 | 1.78 | 4.01 | 127,933 | 7,323,853 | |
2012-11-09 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 8,800 | 1,034,858 | 0.86 | 4.08 | 35,915 | 4,223,462 | |
2012-11-09 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 14,300 | 1,795,927 | 0.80 | 4.08 | 58,361 | 7,329,537 | |
2012-11-08 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 40,000 | 3,750,277 | 1.08 | 12.00 | 479,828 | 44,987,198 | |
2012-11-02 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 4,076 | 741,627 | 0.55 | 14.99 | 61,096 | 11,116,395 | |
2012-11-02 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 12,515 | 737,551 | 1.73 | 15.26 | 190,926 | 11,251,931 | |
2012-11-02 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 21,500 | 1,026,058 | 2.14 | 4.05 | 87,150 | 4,159,126 | |
2012-11-02 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 36,100 | 1,781,627 | 2.07 | 4.05 | 146,331 | 7,221,825 | |
2012-11-02 |
|
4 | TRGT |
TARGACEPT INC
CommonStock |
P - Purchase | 23,400 | 1,004,558 | 2.38 | 4.05 | 94,688 | 4,064,944 | |
2012-11-02 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 6,700 | 1,745,527 | 0.39 | 4.05 | 27,112 | 7,063,275 | |
2012-11-02 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 5,300 | 981,158 | 0.54 | 4.06 | 21,495 | 3,979,283 | |
2012-11-02 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 46,700 | 1,738,827 | 2.76 | 4.06 | 189,401 | 7,052,161 | |
2012-09-10 | 3 | TRGT |
TARGACEPT INC
Common Stock, $0.001 par value |
1,692,127 | ||||||||
2012-09-10 | 3 | TRGT |
TARGACEPT INC
Common Stock, $0.001 par value |
975,858 | ||||||||
2012-09-10 | 3 | TRGT |
TARGACEPT INC
Common Stock, $0.001 par value |
349,482 | ||||||||
2012-08-31 | 3 | CCXI |
ChemoCentryx, Inc.
Common Stock, $0.001 par value |
651,640 | ||||||||
2012-08-31 | 3 | CCXI |
ChemoCentryx, Inc.
Common Stock, $0.001 par value |
376,150 | ||||||||
2012-08-31 | 3 | CCXI |
ChemoCentryx, Inc.
Common Stock, $0.001 par value |
3,710,277 |